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1. Motivation 
The methionine pathway covers the metabolism and catabolism of the essential 
amino acid methionine and overlaps with the polyamine synthesis. The S-
adenosylated derivative of methionine, S-adenosyl-L-methionine (SAM) is an 
important methyl group donor in transmethylation reactions, whereupon S-adenosyl-
L-homocysteine (SAH) is formed. SAM can also be decarboxylated and afterwards 
donates its n-propylamine group to the biosynthesis of the polyamines spermidine 
and spermine from putrescine. In this reaction 5’-deoxy-5’-methylthioadenosine 
(MTA) is formed. MTA can be recycled to methionine, the first step of this catabolism 
is an enzymatic reaction catalyzed by the enzyme methylthioadenosine 
phosphorylase (MTAP, EC 2.4.2.28). 
It has been observed that many malignant tumors commonly lack or display reduced 
MTAP activity and therefore MTA should accumulate in tumors. 
Aim #1: Development of a method to quantify MTA in biological samples. 
A major obstacle in the study of MTA and its role in cancer development and 
progression has been the lack of a sensitive and specific analytical method for its 
direct quantification in cell lysates, cell culture media and tumor tissue specimens. 
Hence, a method for quantification of MTA was developed. Reversed phase liquid 
chromatography combined with electrospray ionization tandem mass spectrometry 
was chosen as analytical method, because of simple sample preparation. Only a 
protein precipitation is necessary to make the sample amenable to LC-MS/MS. To 
achieve high accuracy and reproducibility a stable isotope labeled standard (13C5-
MTA) was synthesized. Low limits of detection and quantification were obtained using 
a triple quadrupole mass spectrometer (API 4000 QTrap) in the MRM mode. With this 
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method the postulated accumulation of MTA in MTAP lacking cells and tissues was 
proved. 
Aim #2: Quantification of intermediates of the methionine and polyamine 
metabolism. 
In an effort to further elucidate the molecular consequences of a lack of MTAP and a 
concomitant increase in intracellular MTA, the analytical method developed under #1 
was expanded to all key intermediates of the methionine and polyamine metabolic 
pathways. The LC separation was optimized including the addition of an ion pair 
reagent and the modification of the gradient. This method was used to determine 
changes in metabolite concentration in these pathways in different cell lines and 
tumor biopsies. 
Aim #3: Determination of the MTAP activity in cell culture samples and liver 
biopsies.  
In the course of the application of the method to tissue specimens from the livers of 
mice with fatty liver disease as well as various tumors, it was observed that the 
protein levels of MTAP did not always correlate with the MTA concentration 
measured in the tissue specimens. In an effort to elucidate whether alterations in 
MTAP activity accounted for the lack of correlation, an LC-MS/MS based assay for 
the measurement of the enzymatic activity of MTAP was developed. Tissue 
specimens were lysed in K2HPO4/KH2PO4 buffer (pH=7.4) and labeled MTA was 
spiked in. To measure the decrease in labeled MTA over time aliquots were taken 
repeatedly over 10 minutes and subjected to LC-MS/MS. Relative rate constants 
were determined and compared between tissues. 
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2. Background 
2.1 5’-Deoxy-5’-methylthioadenosine 
5’-deoxy-5’-methylthioadenosine (MTA) is a modified analogue of adenosine with the 
5’-hydroxy group of the sugar moiety being substituted by a methylthio-group (see 
Figure 1). 
 
Figure 1: Structure of Adenosine and MTA. 
MTA is synthesized from S-adenosyl-L-methionine (SAM), which is a condensation 
product of adenosine and L-methionine. SAM is decarboxylated and the n-
propylamine group of the decarboxylated SAM (dcSAM) is used in the course of 
polyamine synthesis resulting in MTA as byproduct [1]. The first step of MTA 
catabolism is the cleavage of MTA to adenine and methylthioribose-1-phosphate, an 
enzymatic reaction catalyzed by MTA phosphorylase (MTAP, EC 2.4.2.28) [2]. The 
removal of accumulated MTA by MTAP is essential for the synthesis of polyamines 
and the salvage of methionine and adenosine [3]. Due to the involvement of MTA in 
polyamine synthesis, MTA is ubiquitously distributed, e.g. in rat tissues at 
concentrations of 2 to 7 nmol per gram fresh tissue weight as determined by HPLC-
UV after sample preconcentration [4]. 
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Studies reported, that cancer cells commonly lack MTAP expression [5-8]. 
Consequently, in MTAP-deficient cancer cells MTA is presumably not metabolized 
but accumulates intracellularly and/or is excreted [9]. This leads to an increased 
invasive potential of these cancer cells due to molecular mechanisms yet to be 
elucidated in detail [3,6,9-11]. Studies on malignant melanoma show that MTAP-
deficiency correlates with tumor invasion and metastasis. In vitro data has shown that 
MTA leads to tumor progression by inducing matrix metalloproteins (MMP) in 
melanoma cells as well as in tumor associated fibroblasts [6,12]. It was furthermore 
observed that in melanoma patients tumor cells lacking MTAP show a worse 
response to interferon therapy [13]. 
Beside its role in tumor progression, MTA also affects cellular signaling pathways. 
Mowen et al. demonstrated that MTA influences the interferon signaling pathway 
caused by the reduction in methylated STAT (signal transducer and activator of 
transcription) which is required for activating the transcription of target genes [14]. 
Although this is critically discussed [6] Meyer et al. could show a positive correlation 
between MTAP expression and a response to an interferon-α treatment in patients 
with malignant melanoma [15]. Hence, MTA is of great interest in the filed of tumor 
research. 
 
2.2 Quantitative analysis of 5’-deoxy-5’-methylthioadenosine 
A major obstacle in the study of MTA and its role in cancer has been the lack of a 
sensitive and specific analytical method for its direct quantification in cell and tissue 
lysates as well as cell culture supernatants. Mass spectrometry has been applied to 
the analysis of urinary MTA. Liquid chromatography coupled to an ion trap MS 
yielded lower limits of detection (LODs) in the lower pmol range [16], while a LOD of 
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100 fmol was achieved using MALDI-TOF-MS [17]. However, data on absolute 
quantification, reproducibility and accuracy were reported for neither method. Further, 
there have been reports on the HPLC separation of MTA and its detection by means 
of UV absorbance [18-20]. Although LODs as low as 1 nmol were obtained using 
boronate affinity chromatography for pre-concentration of MTA, LC-UV has proven 
too insensitive and insufficiently selective for the direct analysis of MTA in tumor 
cells. 
 
2.3 Methionine and polyamine metabolism 
Since the analysis of MTA alone is insufficient to evaluate metabolic changes during 
the development and progression of a disease, the comprehensive analysis of 
intermediates of the methionine and polyamine metabolism is needed to understand 
the underlying mechanisms of these metabolic changes. Methionine is one of two 
sulfur-containing proteinogenic amino acids. Other than in protein synthesis, 
methionine plays an important role in the biosynthesis of cysteine, carnitine, taurine, 
and lecithine [21-23]. Its S-adenosylated derivative, S-adenosylmethionine (SAM), is 
an important methyl group donor in transmethylation reactions, whereupon S-
adenosyl-L-homocysteine (SAH) is formed (Figure 2) [24]. SAH is hydrolyzed 
enzymatically to homocysteine and adenosine, and the former is recycled back to 
methionine through transfer of a methyl group from 5-methyltetrahydrofolate by the 
enzyme 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR, EC 
2.1.1.13) [25]. SAM can also be decarboxylated by adenosylmethionine 
decarboxylase (AMD1, EC 4.1.1.50) to S-adenosylmethionineamine (dcSAM), which 
subsequently donates its n-propylamine group in the biosynthesis of spermidine and 
spermine from putrescine, whereupon MTA is formed (Figure 2) [1]. MTA, in turn, can 
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be recycled back to methionine, the first step of which involves the phosphorolytic 
cleavage of MTA by methylthioadenosine phosphorylase (MTAP, EC 2.4.2.28) to 
produce adenine and 5'-deoxy-5'-(methylthio)ribose-1-phosphate [2,3]. 
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Figure 2: Scheme of the methionine and polyamine pathways. 
Polyamines derive from the amino acid ornithine, which is decarboxylated in the initial 
rate-limiting reaction by the enzyme ornithine decarboxylase (ODC, EC 4.1.1.17) to 
yield putrescine [26]. Subsequently, putrescine gives rise to spermidine, which in turn 
provides the substrate for the formation of spermine. Polyamines play important roles 
in cellular growth, differentiation of eukaryotic cells, conformational stabilization of 
nuclear DNA, and methylation of tRNA. Acetylation of polyamines is required in the 
homeostatic maintenance of polyamine levels in mammalian cells within a relatively 
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constant range by rendering polyamines susceptible to either export out of the cell or 
enzymatic oxidation to lower polyamines [27]. 
Many malignant tumors lack or display reduced MTAP activity [3,6,10] resulting in an 
accumulation of MTA in MTAP lacking cells [12,28]. Polyamines are also known to 
concentrate in cancer cells and it has been reported that MTAP regulates ornithine 
decarboxylase (ODC) activity by downstream metabolites [29]. However, to date 
analytical methodology for the combined analysis of intermediates of both the 
methionine cycle and polyamine biosynthesis has lacked. In 2009 Cataldi et al. 
published a method using liquid chromatography coupled to hybrid linear quadrupole 
ion trap and Fourier transform ion cyclotron resonance mass spectrometer for the 
analysis of the methionine pathway including adenine, adenosine, homocysteine, 
homocystine, MTA, methionine, SAH and SAM [30]. In addition, methods have been 
developed for the determination of selected metabolites of either pathway. 
Methods to quantify SAM and SAH by LC-MS/MS were developed by Gellekink et al. 
[25] and Krijt et al. [31]. Polyamines and their acetylated derivatives, on the other 
hand, have been determined by LC-MS/MS as carbamoyl [32] or as benzoyl 
derivatives by LC-UV [33]. Hakkinen et al. presented an LC-MS/MS method to 
quantify polyamines without derivatization [34]. Kammerer et al. determined MTA and 
adenosine after analyte enrichment by LC-IT-MS [16] and Porcelli et al. determined 
only MTA without prior enrichment by LC-UV [18]. For the analysis of amino acids 
numerous analytical methods are available, including GC-MS [35], LC-UV [36], CE-
MS [37]. An IP-LC-MS method [38] includes additionally the quantification of 
homocysteine.  
A comparison of these methods containing analytes and figures of merit is given in 
Table 1 on the next page. 
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Table 1: Method comparison for quantification of metabolites of the methionine and polyamine 
pathways. 
Method Analytes a LOD LOQ Ref. 
LC-FTICR-MS Complete methionine pathway 0.01 – 1.8 µM 0.03 – 5.9 µM [30] 
LC-QqQ-MS SAM  SAH n.d. 
2 nM 
1 nM [25] 
LC-QqQ-MS SAM  SAH 
7.5 nM 
15 nM n.d [31] 
Carbamoyl derivatization and 
LC-IT-MS 
Putrescine 
Ac-putrescine 
Spermidine 
Ac-spermidine 
n.d. 1 ng/mL [32] 
Benzoyl derivatization and 
LC-UV 
Putrescine 
Spermidine 
Spermine 
057 pmol abs. 
117 pmol abs. 
124 pmol abs. 
n.d [33] 
No derivatization and  
LC-QqQ-MS 
Putrescine 
Spermidine 
N1-Ac-spermidine 
N8-Ac-spermidine 
Spermine 
ac-Spermine 
n.d. n.d. [34] 
LC-IT-MS Adenosine MTA 0.1-9.6 pmol abs. n.d. [16] 
MALDI-TOF-MS Adenosine MTA 100 fmol abs. n.d. [17] 
LC-UV MTA 1 mM n.d. [18] 
Propyl chloroformate 
derivatization and GC-MS 
Methionine 
Ornithine 
0.9 µM 
0.3 µM 
3.0 µM 
0.9 µM [35] 
Ninhydrin derivatization and 
LC-UV 
Methionine 
Ornithine < 5 µM n.d. [36] 
CE-QqQ-MS Methionine Ornithine 
0.7 µM 
0.5 µM n.d. [37] 
No derivatization and  
LC-QqQ-MS 
Methionine 
Ornithine 
Homocysteine 
n.d. 0.4 µM [38] 
 a Only analytes of interest for this work are selected. 
2.4 Kinetic studies of methylthioadenosine phosphorylase 
The accumulation of MTA is not necessarily an indication of lower MTAP abundance, 
but can also point towards reduced MTAP activity. This can be assessed by 
measuring the enzymatic activity of MTAP. In the past only a few experiments were 
carried out to determine kinetic parameters of the MTAP enzyme. In 1984 Seidenfeld 
et al. described for the first time an assay to determine MTAP activity in rat prostate 
based on the use of 14C-labeled MTA [4]. Six years later, based on this assay, Della 
Ragione et al. purified and characterized MTAP in human placenta and analyzed 
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MTAP activity [2]. Cacciapuoti measured MTAP activity in different types of 
archaeons (thermophilic bacteria) under high thermal conditions (70-80°C) [39-41]. 
All these assays are radio isotope assays and based on measuring the formation of 
[methyl-14C]-5-methylthioribose-1-phosphate from [methyl-14C]-MTA. The use of 
stable isotope labeled substrate and the analysis of substrate degradation by LC-
MS/MS has not been described yet. 
 
2.5 Mass spectrometry for metabolic profiling 
Metabolomics aims at the comprehensive quantitative analysis of all low-molecular 
weight metabolites in a biological system [42]. Two complementary strategies are 
used in the field of metabolomics: metabolic fingerprinting and metabolic profiling. 
Metabolic fingerprinting is the comparison of metabolic patterns (the fingerprint of a 
sample), that change during disease, toxin exposure, environmental or genetic 
alterations. This method does not intend to identify and quantify single metabolites, 
but to visualize metabolic differences between samples [42]. 
The second approach, metabolic profiling, is the qualitative and quantitative 
determination of selected analytes for example in a metabolic pathway or compound 
class. Analysis of amino acids is an example for metabolic profiling. A more direct 
approach of metabolic profiling is target analysis, where selected metabolites are 
measured, such as substrates, intermediates and products of enzymatic reactions 
[43]. In most cases, as in this work, metabolic profiling is hypothesis-driven. 
Metabolites are selected and analytical methods for quantification are developed to 
test a given hypothesis. In the present work, the metabolic consequences of a lack of 
MTAP with regards to up- and downstream metabolites in the methionine and 
polyamine pathways are under investigation. 
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An often used strategy for metabolic profiling experiments is the separation of the 
metabolites by a chromatographic technique and the detection and quantification for 
example by mass spectrometry. The chromatographic separation tremendously 
expands the capability for the analysis of complex samples [44]. Different types of 
mass spectrometers have been developed over time and are well suited for 
metabolite detection in profiling analysis. 
 
2.5.1 Single quadrupole mass spectrometer 
A quadrupole mass analyzer (qMS) consists of four circular parallel rods. A direct 
current is placed on pairs of opposing rods and overlaid with a radiofrequency. Ions 
are separated based on the stability of their trajectories in the electric field applied to 
the rods. At a given voltage ratio only ions of a certain m/z can pass through the 
quadrupole, while all others move on unstable trajectories. By changing the voltage 
ratio ions are successively scanned. 
A single quadrupole mass spectrometer contains only one quadrupole and can be 
operated in two different modes, the full scan and the selected ion monitoring (SIM) 
mode. In the full scan mode the instrument scans the complete selected mass range, 
in the SIM mode only single selected masses are analyzed. The use of the SIM mode 
results in the advantage of either a higher duty cycle or in a longer scan time per 
mass. The higher duty cycle delivers more points over chromatographic peak 
meanwhile a longer scan time per mass results in a higher signal and better limits of 
detection (LODs) and lower limits of quantification (LLOQs) of the analytes. Using a 
single-quadrupole mass spectrometer combined with a GC it is possible to achieve 
LODs and LLOQs in the nanomolar range [35]. 
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2.5.2 Time-of-flight mass spectrometer 
In a Time-of-flight mass spectrometer (TOFMS) ions are accelerated by an electric 
field of known strength. This results in an identical kinetic energy of the accelerated 
ions and the velocity of the ions depends on their mass-to-charge ratio. Ions are 
pushed during the acceleration in a filed-free drift tube, the time the ions need to 
travel a given distance until they reach the detector is measured and the m/z ratio is 
calculated. Ions are pushed periodically into the field free flight tube. The pusher 
frequency is determined by the time required until the slowest ion reaches the 
detector. The first TOFMS-instruments were designed linear, i.e. the ions beam in the 
source has the same direction as the acceleration and the drift region. The detector is 
positioned at the end of the drift region [45]. To compensate for the energy spread of 
the ions during the acceleration in newer instruments a reflector is installed in the drift 
tube. This reflector doubles the length of the field-free drift and focuses identical ions 
with an energy spread [46]. To minimize the effects of energy spread an orthogonal 
acceleration was developed. The ion beam leaving the source is accelerated 
orthogonally into the field-free drift region. This minimizes the energy spread of the 
ions as a result of ionization and transfer to the accelerator [47]. 
TOFMS has only one operation mode, the mass range scan. The selected scan 
range has no influence on peak intensity, since the instrument does not change the 
acceleration frequency of the ions. Smaller scan ranges reduce only the size of the 
acquired data file of the analysis. Coupled to liquid chromatography LODs and 
LLOQs in the lower nanomolar range can be achieved [48-50], while in combination 
with capillary electrophoresis LODs and LLOQs are in the lower micromolar range 
[51]. A big advantage of TOFMS over qMS is the high mass accuracy with an error in 
the range of 2-5 ppm, which allows the generation of a possible molecular formula of 
 - 12 - 
the detected ion. This feature can be used in metabolic fingerprinting to identify 
unknown compounds [52]. 
 
2.5.3 Triple quadrupole mass spectrometer 
A triple quadrupole mass spectrometer, one type of a tandem mass spectrometer, 
consists of two quadrupoles, with a non mass resolving quadrupole in between. The 
first (Q1) and the third quadrupole (Q3) function as a mass filter, whereas the second 
quadrupole (q2) is used as a collision cell to provide collision-induced fragmentation 
of precursor ions selected in Q1. The fragments pass Q3, where they are scanned or 
filtered. Consequently, the instrument can be described as a “double single quad”. 
The combination of two mass filters and fragmentation enables different operation 
modes, such as product ion scan (PI), precursor ion scan, neutral loss scan and 
multiple reaction monitoring (MRM).  
The PI scan is used to get structural information about an analyte. One quasi-
molecular ion is selected in Q1, fragmented in q2 and the fragments are scanned in 
Q3. A precursor ion scan has the same principle as a PI scan, but the Q1 is scanned 
and Q3 filters one fixed mass out of the formed fragments. Thus defined precursor 
ions, e.g. glycosylated peptides, can be determined in a complex mixture due to 
formation of specific fragments [53]. During a neutral loss scan ions are scanned in 
Q1, fragmented in q2, and fragment ions with a given offset are scanned in Q3. 
Consequently, Q1 and Q3 are working in a dependent scan mode, i.e. the masses of 
Q1 and Q3 are synchronized and the mass of Q3 is reduced by the mass of the 
neutral loss to be analyzed (e.g. -44 for CO2 in organic acids). 
The triple quadrupole mass spectrometer is highly suitable for selective and sensitive 
quantification [54] by selecting the quasi molecular ion in Q1 and filtering the most 
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abundant fragment in Q3 out instead of scanning all fragments. This mode of double 
mass filtering is called MRM and yields the best LODs and LLOQs in the lower 
nanomolar range [55], since interfering noise is filtered out twice. 
 
2.5.4 Quadrupole time-of-flight mass spectrometer 
A quadrupole-time-of-flight mass spectrometer (qTOFMS) is a hybrid tandem mass 
spectrometer. It is constructed like a triple quadrupole but the third quadrupole is 
exchanged by a time-of-flight mass analyzer. This instrument can either be used as a 
TOFMS, to determine molecular masses with high accuracy, or as a triple quadrupole 
mass spectrometer. All fragments of the precursor ion selected in Q1 will be acquired 
and their masses will be determined with high accuracy. As mentioned above in the 
TOFMS section, the detector is pulsed and it is not possible to increase peak 
intensity by lowering the scanned mass range. Hence, this instrument is not as 
sensitive as the triple quadrupole mass spectrometer However, it offers the 
advantages that structural information and exact masses of the quasi-molecular ion 
and the resulting fragment ions can be determined. This type of instrument is 
commonly used in the field of proteomics [56], but also in metabolic studies, e.g. the 
transformation of tetrazepam to diazepam in the human body [57]. Furthermore this 
type of mass spectrometer can be used like a TOFMS in the field of metabolic 
fingerprinting and identification of unknowns [58,59]. 
 
2.5.5 Triple quadrupole linear ion trap (QTrap) 
A QTrap mass spectrometer is a triple quadrupole mass spectrometer, where the 
third quadrupole can be used as a linear ion trap. By placing on lens each before and 
after Q3 it is possible to trap and accumulate ions in Q3. The benefit is a higher 
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sensitivity in the scan mode compared to a pure triple quadrupole instrument. Also, 
MS3 experiments can be performed by using the trap function and successive MS 
experiments, e.g. a product ion scan in the trap after a MRM event [60-62]. To work 
in accordance with the GLP-rules it is necessary to use two MRM transitions 
(quantifier and qualifier trace) for identification of a metabolite [63]. This doubles the 
duty cycle of the instrument. Using a QTrap instrument an information dependent 
acquisition (IDA) experiment can be performed, e.g. a product ion scan in the linear 
ion trap after the occurrence of a MRM signal [64]. To confirm the presence of the 
metabolite, which causes the MRM signal at the expected retention time, this 
fragmentation pattern can be used instead of the second MRM (qualifier) trace. Since 
such an IDA experiment is faster than two MRM scans, the duty cycle will decrease 
and additional information (product ions) will be obtained [65,66]. 
 
2.6 Stable isotope techniques 
Correct quantification is a major issue in analytical chemistry requiring appropriate 
calibration of the used system. In case of concentration analysis this can be 
performed by an external or an internal calibration.  
With an external calibration the concentration of the analyte is determined by a 
calibration curve, which is acquired using standards at different concentration levels. 
An advantage of this method is the high sample throughput, because no additional 
calibration work, e.g. adding internal standards, has to be performed on each sample. 
A correction for variability during sample preparation and analysis is not possible. 
The addition of a known amount of a standard compound which is not present in the 
sample (e.g. norleucine in amino acid analysis) is a first approach to account for this. 
It corrects to some extent for problems during sample preparation and analysis, but 
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not for all, because the used standard is only similar but not identical with the 
analytes of interest. In liquid chromatography-mass spectrometry ion suppression is 
an additional problem [67]. It occurs during ionization if the ionization energy is not 
high enough to ionize all analyte molecules. Since not all analytes have the same 
ionization efficiency, different percentages of each analyte will be ionized. This effect 
depends on coeluting matrix components and varies during the chromatographic run 
and therefore a correction for ion suppression is not possible with only one standard. 
The best way to correct for ion suppression and other matrix effects is to add a 
known amount of a stable isotope labeled analog of the analyte of interest, e.g. 13C, 
15N or 2H labeled compounds. These stable isotope labeled standards have the 
advantage that they show identical chemical, nearly identical physical properties and 
they are not radioactive. In case of liquid chromatography coupled to mass 
spectrometry analyte and standard show the same behavior during sample 
preparation, injection into the system, chromatographic separation (using deuterated 
internal standards a partial separation from the unlabeled analyte is possible) and 
ionization in the mass spectrometer. A distinction between analyte and stable isotope 
labeled standard is done by the mass spectrometer, where analyte and standard 
show different masses. A corresponding stable isotope labeled standard corrects the 
best for problems during sample preparation and analysis and the quantification of 
the analyte is as exact as possible. 
Quantification can be performed with the ratio analyte / stable isotope labeled 
standard only, so called isotope dilution analysis [68]. The amount of stable isotope 
labeled standard, which causes the signal, is known and the analyte concentration is 
calculated as the ratio of both signals. Alternatively, a calibration curve using a 
standard dilution spiked with a known amount of stable isotope labeled standard can 
be generated. The calibration curve with internal standard is a combination of isotope 
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dilution analysis and quantification with an external calibration. This method (used in 
the presented work) allows a precise determination of LOD and LLOQ as well as 
quantification of analytes in the samples. A correction for problems during sample 
preparation and analysis is possible. 
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3. Quantification of 5’-deoxy-5’-methylthioadenosine 
3.1 Introduction  
The aim of the study was to develop a method to quantify 5’-deoxy-5’-
methylthioadenosine (MTA) in various biological samples. As its structural analogue 
adenosine MTA is accessible for a direct analysis by reversed phase liquid 
chromatography coupled to mass spectrometry without any steps of derivatization. 
Consequently, no complex sample preparation is necessary, but a simple protein 
precipitation with methanol is used, to avoid column blocking. To achieve a good 
linearity and low detection and quantification limits, a stable isotope labeled internal 
standard was used. A shortened version of this chapter was published in the Journal 
of Chromatography B [28]. Parts of the results are also shown in [12]. 
 
3.2 Experimental 
3.2.1 Chemicals 
All solvents for sample preparation and LC-MS were HPLC grade and purchased 
from Fisher-Scientific (Schwerte, Germany). MTA was obtained from Sigma Aldrich 
(Taufenkirchen, Germany) and labeled adenosine from Omicron Biochemicals (South 
Bend, IN, USA). The water used was purified by means of a PURELAB Plus system 
(ELGA LabWater, Celle, Germany). All chemicals for synthesizing labeled MTA 
(thionylchloride, pyrimidine, ammonia and sodium methanethiolate) were purchased 
from Fluka (Taufenkirchen, Germany). 
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3.2.2 Internal standard preparation 
Stable isotope labeled [1’,2’,3’,4’,5’-13C5]-MTA was synthesized in house according to 
Robins et al. [69]. A scheme of the synthesis is shown in Figure 3. 
 
Figure 3: Scheme of the synthesis of methylthioadenosine as described by Robins et al. [69].  
102 mg of 13C5-labeled adenosine (1) were dissolved in a mixture of 0.1 mL pyridine 
and 1.5 mL acetonitrile. Cooled in an ice bath 0.15 mL thionylchloride were added 
drop wise and the reaction mixture was allowed to warm up over night. The solvents 
were removed by evaporation and the formation of white crystals (2) was observed 
(reaction step 1, method c). The crystals (2) were dissolved in a mixture of 2.5 mL 
methanol and 0.5 mL water. Afterwards 0.25 mL concentrated ammonia solution was 
added and the solution got a red color, presumably caused by rests of pyridine. The 
reaction mixture was stirred over 1 h at room temperature and the solvents were 
again evaporated. The reaction product (3) formed white crystals. The third step was 
made a little bit easier, due to the direct use of sodium methanethiolate instead of 
forming it in situ by the reaction of sodium hydrate and methanethiol. The product of 
step two (3) was dissolved in 3 mL dimethylformamide and 30 mg of sodium 
methanethiolate (dissolved in 2 mL dimethylformamide) were added dropwise to the 
stirred solution. During the reaction the reaction mixture was cooled at -30°C and 
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was allowed to warm up to ambient temperature after finishing the reaction. The 
mixture was stirred over night and the solvents were removed by evaporation. The 
residue was dissolved in 2.5 mL water, neutralized with HCl and cooled in the fridge. 
The crude product (4) was purified by recrystalization from MeOH/water (1:1, v/v, 10 
mL). An overall yield of 29.7% (theoretical value 74.3%) was achieved and the stable 
isotope labeled MTA had an isotopic purity of 94%. A possible explanation of the 
lower yield could be the modification of the third step of the synthesis. This 
modification makes the synthesis easier, but could decrease the reaction efficiency. 
Furthermore the intermediate products were not purified during the synthesis and 
therefore side reactions are possible reason for the lower yield. The reason for the 
diminished isotopic purity was not found, the missing purification of the intermediate 
products in no reason therefore, because the unlabeled reagents alone can not form 
MTA. 
A 2.24 mM stock solution of [1’,2’,3’,4’,5’-13C5]-MTA in water was prepared and 
further diluted with water to obtain a working solution of 224 nM, which was spiked 
into the samples and calibration standards. The final concentration of the internal 
standard in samples and standards was 22.4 nM. 
A stock solution of unlabeled MTA was prepared in water and serially diluted over a 
concentration range of 1.0 mM to 12.5 pM. Spiking with internal standard was 
performed immediately before calibration. For calibration, 10 µL of internal standard 
were transferred into a 0.2-mL micro-insert (VWR, Darmstadt, Germany) in a 1.5-mL 
glass vial (Fisher-Scientific), dried by evaporation using an infrared vortex-vacuum 
evaporator (CombiDancer, Hettich AG, Bäch, Switzerland), and then reconstituted 
with 100 µL of the respective aqueous MTA standard. 
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3.2.3 Cell culture experiments and cell harvesting 
The melanoma cell line Mel Im has been described in detail previously [70]. Further, 
two clones of Mel Im that either lack (Mock D) or express (Clone 5) MTAP were used 
[6]. Cells were grown at 37°C / 5% CO2 in Dulbecco's modified Eagle medium 
(DMEM; PAN Biotech GmbH, Aidenbach, Germany) supplemented with penicillin 
(400 U/mL), streptomycin (50µg/mL), L-glutamine (300µg/mL) and 10% fetal calf 
serum (FCS; Sigma, Deisenhofen, Germany). 
Melanoma cells, 200,000 each, were seeded in FalconTM six-well-plates (Becton 
Dickinson GmbH, Heidelberg, Germany) and cultured in 2 mL DMEM as described 
above, for different periods of time. If not stated otherwise, cells were cultured for 
24 h and were then harvested with trypsin (PAN Biotech GmbH). Cell culture medium 
samples were transferred in Eppendorf Cups and stored at -80°C until further 
preparation. 
The adherently growing cells used in this study were harvested by incubation in 200 
µL of either a solution containing 0.05% (w/v) trypsin and 0.02% (w/v) EDTA or 5 mM 
EDTA only. Trypsination was stopped after 5 min with 700 µL of cell culture medium. 
Following centrifugation at 100xg (5 min, room temperature), the supernatant was 
removed and the cell pellets were stored at -80°C until extraction. Alternatively, cells 
were scraped directly in pure methanol. To that end, 500 µL methanol spiked with 
2.48 nmol/L stable isotope labeled MTA were added to the well after the cell culture 
medium had been removed and the cells were washed twice with 500 µL PBS buffer 
each. Cells were scraped, centrifuged (100xg, 5 min, room temperature) and the 
supernatant was collected. The cell pellet was washed twice with 200 µL methanol, 
centrifuged and all supernatants were combined. After drying and reconstitution in 
100 µL of water the concentration of the internal standard should be 22.4 nM in case 
of 100% recovery. 
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The experimental work described in chapter 3.2.3 was performed by Susanne 
Wallner in the working group of Prof. Anja Bosserhoff at the Institute of Pathology, 
University of Regensburg. 
 
3.2.4 Extraction of 5’-deoxy-5’methylthioadenosine from cell culture 
media 
Methanol (600 µL) was added to 200 µL cell culture medium, followed by the addition 
of 10 µL internal standard (224 nM). The sample was vortexed and centrifuged at 
9,000xg for 5 min at 4°C. The supernatant was transferred to a glass vial. The protein 
pellet was washed twice with 200 µL methanol and all supernatants were combined. 
The solvent was evaporated and the residues were reconstituted in 100 µL water. 
A matrix spike and a standard addition experiment were carried out in cell culture 
media to check the efficiency of the extraction procedure and to evaluate ion 
suppression. To generate a representative matrix sample, 500-µL aliquots from 13 
different cell culture media samples were combined. For the matrix spike experiment, 
aliquots of 200 µL of the matrix sample were spiked with MTA at three molar levels 
(resulting in final concentrations of 50 nM, 75 nM and 100 nM of MTA after 
reconstitution) and extracted as described above. For the standard addition, 200-µL 
aliquots of the matrix sample were extracted as described above. The obtained 
extract was then spiked with MTA at three levels (resulting in final concentrations of 
50 nM, 75 nM and 100 nM after reconstitution). All samples were fortified with stable 
isotope labeled internal standard prior to extraction. 
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3.2.5 Extraction of 5’-deoxy-5’-methylthioadenosine from cell pellets 
For the extraction of MTA from cell pellets, different solvent combinations (MeOH, 
MeOH/H2O 50:50 v/v, acetonitrile, and acetonitrile/H2O 50:50 v/v) were tested. 
Briefly, 600 µL of the different solvents were added to the frozen pellets and internal 
standard was spiked as described above. Then, the sample was slowly thawed on 
ice. To complete the cell lysis the cells were again shock-frozen in liquid nitrogen and 
thawed on ice. The freeze/thaw cycle was performed three times and the sample was 
vortexed in between each cycle. The sample was centrifuged at 9,000xg for 5 min at 
4°C and the supernatant was transferred to a 1.5-mL glass vial. The pellet was 
washed twice with 200 µL of methanol and all supernatants were combined. The 
extract was further treated as described above. 
For cell pellets, a standard addition experiment was carried out to evaluate ion 
suppression. The cell pellets were prepared as described above and a representative 
set of cell extracts was pooled. The experiment was carried out with cells removed by 
trypsin and EDTA, respectively. Ten µL of MTA standard solution with concentrations 
of 2.5, 5.0 and 7.5 µM were dried and then reconstituted with 100 µL of the pooled 
cell extracts. All concentrations were prepared in triplicate. 
 
3.2.6 Lysis of malignant melanoma tissue samples 
In a first approach we were interested, if the hypothesized accumulation of MTA can 
be observed in melanoma tumors. For that purpose biopsies (approx. 10-20 mg, 
tumor n=5 and healthy skin n=3) were weighted and then lysed in 50 µL of water by 
freezing in liquid nitrogen and thawing on ice. This freeze-thaw-cycle was performed 
three times and the lysates were treated afterwards as described above for the cell 
media pretreatment. 
 - 23 - 
The experimental work described in chapter 3.2.6 was performed by Susanne 
Wallner in the working group of Prof. Anja Bosserhoff at the Institute of Pathology, 
University of Regensburg. 
3.2.7 Analysis of 5’-deoxy-5’-methylthioadenosine in cell culture 
supernatants of different tumor cell lines and primary cells 
Measurements of MTA were performed in the supernatants of different primary cell 
and tumor cell line cultures. Cell lines studied and their respective origins are listed in 
Table 2. Either 1.0 or 2.5 million cells were cultivated in six well plates (Corning, 
Amsterdam, The Netherlands) over 24 h at 37°C / 5% CO2. The volume of the cell 
culture medium was adjusted to the cell count, i.e. 1.0 million cells were cultivated in 
1.6 mL and 2.5 million cells in 4.0 mL. After 24 h cell culture medium was taken and 
stored at -80°C until further preparation. 
Table 2: Cell type and name of the different cell lines and primary cells used for measurement 
of MTA in cell culture media. 
Cell type Cell line 
Bladder carcinoma J82, RT4 
Brain tumor initiating cells RAV 21, RAV 26 
Colon adenocarcinoma SW480, SW620 
Breast carcinoma MDA-MB-231, SKB R3, T47D 
Glioblastoma U87 
Leukemia Jurkat, THP-1 
Melanoma B16.SIY.E12 (mouse), Mel Im, Na8 
Primary cells CD8, Monocytes 
Renal cell carcinoma RCL1503, RH-556, RJ494 
The experimental work described in chapter 3.2.7 was performed by Gabriele 
Hartmannsgruber in the working group of Dr. Eva Gottfried / Prof. Marina Kreutz at 
the Institute of Hematology and Oncology, University of Regensburg. 
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3.2.8 Instrumentation 
Liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-
MS/MS) was performed using an Agilent 1200 SL HPLC system (Böblingen, 
Germany) and a PE Sciex API 4000 QTrap mass spectrometer (Applied Biosystems, 
Darmstadt, Germany), which was equipped with a turbo ion spray source (completely 
controlled by Analyst version 1.4.2). The column oven was kept at 25°C. An Atlantis 
T3 3µm (1.0 i.d. x 150 mm) reversed phase column (Waters, Eschborn, Germany) 
was used. LC separation was carried out using a mobile phase consisting of 0.1% 
acetic acid in water (Solvent A) and 0.1% acetic acid in acetonitrile (Solvent B). The 
gradient employed was as follows: 0-10 min linear increase from 0% to 100% solvent 
B, hold at 100% solvent B for 5 min. The flow-rate was set to 125 µL/min. Sample 
volumes of 10 µL were injected. 
The API 4000 QTrap mass spectrometer was operated in positive mode using turbo 
ion spray with the following parameters: gas 1 as 50, gas 2 as 30 and the curtain gas 
as 10 (all arbitrary units). The turbo ion spray source was heated to 250°C. The 
declustering potential was set to 60.0 V and the entrance potential to 10.0 V. 
Quantitative determination was performed in the multiple reaction monitoring (MRM) 
mode using the following ion transitions: m/z 298.2 (M+H)+ to m/z 136.1 (product ion) 
for MTA and m/z 303.2 (M+H)+ to m/z 136.1 (product ion) for the internal standard 
(13C5-labeled MTA). Collision-induced dissociation was performed with nitrogen as 
collision gas. The collision energy and the collision exit potential were set at 23 eV 
and 9 V, respectively. The electron multiplier was set to 2100 V. All MS parameters 
were optimized by direct infusion and the source parameters by flow injection. Data 
analysis was performed using Analyst version 1.4.2. 
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3.2.9 Data analysis 
Standard calibration curves were plotted as the chromatographic peak area ratio 
(MTA / IS) versus the corresponding nominal concentration ratio (MTA / IS). A 1/x2 
weighted regression analysis was used to determine the slope, intercept and 
coefficient of determination (r2). A two-tailed, unpaired, homoscedastic t-test was 
used to determine whether the means of the intra- and extracellular amounts of MTA 
measured in Mel Im clones either lacking or expressing MTAP were significantly 
different (p < 0.05). The same test was used to check whether the change of MTA 
concentration in FCS supplemented cell culture medium was significantly different.  
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3.3 Results and Discussion 
3.3.1 Method validation 
Figure 4 shows a product ion spectrum of MTA after ionization in positive mode. At 
m/z 298.2, the quasi molecular ion of MTA occurs and the main product ion is the 
protonated adenine at m/z 136.0, which was used to set up the MRM transition for 
quantitative analysis. The fragment at m/z 163.0 is the complementary fragment of 
the main product ion, the sugar group which is lost by forming the protonated 
adenine. 
 
Figure 4: Product ion spectrum of MTA. 
Representative MRM-chromatograms of an MTA standard, a cell culture medium 
sample and a cell pellet sample are shown in Figure 5. As can be seen, MTA elutes 
as a symmetric peak without any interferences even in the sample extracts. 
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Figure 5: MRM-chromatograms of co-eluting unlabeled and stable-isotope labeled MTA (minor 
peak). (A) MTA standards, and methanol extracts of (B) cell culture medium and (C) Mel Im cell 
pellet. 
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A calibration was carried out using standards in the range of 12.5 pM to 1 mM. 
During analysis, it was observed that the internal standard contained small amounts 
of unlabeled MTA. Therefore, a calibration without internal standard was performed 
to determine the instrumental detection limit. This resulted in a limit of detection 
(LOD) of 62.5 pM at a signal to noise ratio (S/N) of 3. The lower limit of quantification 
(LLOQ) was defined as five times the background MTA level. Due to the 
contamination of the internal standard with unlabeled MTA the LLOQ was 2 nM and 
could be determined with an accuracy of 100.15% and an imprecision of 2.96%. This 
concords well with the FDA guidelines for bioanalytical method validation that require 
an analyte response at the LLOQ of at least 5 times the response compared to a 
blank and an accuracy and imprecision of 80-120% and <20%, respectively [71]. The 
calibration curve was linear from the LLOQ to 1 µM (intercept: 0.0212; slope: 0.949; 
r2: 0.999). The relative standard deviation (RSD) of triplicate injections was 1.77%. 
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A matrix spike and a standard addition experiment of MTA in cell culture medium 
samples were carried out using three spike levels. Each experiment was performed 
in triplicate. Figure 6 shows the results in comparison to the calibration curve over 
this concentration range.  
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Figure 6: Matrix spike and standard addition experiment for cell media versus calibration curve 
with internal standard correction. 
RSD values for triplicate samples in the matrix spike and standard addition ranged 
from 1.3 – 7.0% and 1.6 – 5.9%, respectively. It can be seen that the internal 
standard corrects very well for potential ion suppression or incomplete extraction 
because the slope of the three curves is similar. To further evaluate the extraction 
efficiency, the absolute areas of the MTA without internal standard correction were 
plotted versus the concentration (Figure 7). 
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Figure 7: Matrix spike and standard addition experiment for cell media versus calibration curve 
without internal standard correction. 
Interestingly, the RSD values were still in the range of 0.9 – 3.9% and 1.9 – 5.2% for 
the matrix spike and standard addition, respectively. Figure 7 shows a nearly 
identical slope for the matrix spike and the standard addition experiment. This 
demonstrates complete extraction of MTA from the sample. Using the values of the 
standard addition experiment as reference, recovery rates were calculated for the 
matrix spike samples, which ranged from 94.6 –112.4%. However, the slope of matrix 
spike and standard addition experiments is only 60% of the slope of the calibration 
curve, indicating substantial ion suppression. This observation is identical to the 
recovery of the internal standard from cell culture media, namely about 60%. 
However, as demonstrated above, the internal standard corrects for the ion 
suppression. 
In addition to MTA excretion into the cell culture media, the intracellular levels were 
determined. For cell pellet extraction (pellets of 1,000,000 cells), different solvent 
combinations (MeOH, MeOH/H2O 50:50 v/v, acetonitrile and acetonitrile/H2O 50:50 
v/v) were tested. Each experiment was performed in triplicate. The highest amount of 
matrix spike and standard addition versus calibration 
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extracted MTA and the best recovery of the internal standard were achieved with 
pure methanol (see Figure 8 A and B). 
 
 
Figure 8: Detected absolute amount of MTA (A) and recovery of internal standard (B) in pellets 
of 1,000,000 cells each using different extraction protocols. 
Metabolite leakage from adherently growing cells during harvesting can present a 
serious problem, if intracellular metabolite concentrations need to be determined. The 
conventional method to release cells is trypsination. In addition, we tested a 
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reportedly less aggressive method, namely a 5-mM EDTA solution. We also tested 
cell harvesting by scraping the cells directly in methanol spiked with IS. This 
procedure combines cell harvesting with cell extraction and should minimize 
metabolite losses caused by leakage. Each experiment was performed in triplicate. 
We observed very similar amounts of extracted MTA using EDTA or trypsination 
(Figure 9). 
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Figure 9: Arithmetic means and standard deviations of intracellular amount of MTA for three 
different cell harvesting procedures after incubation of 200,000 seeded Mel Im cells for 24 h. 
With the methanol scraping protocol, the amount of extracted MTA was about 40% 
higher than for the other two methods (Figure 9). Hence, cell leakage must be similar 
for EDTA and trypsination. However, direct scraping does not allow the determination 
of cell count, a parameter often used for normalization in cell culture experiments. 
Overall, trypsination allowed the extraction of MTA and recovery of internal standard 
with the lowest imprecision, namely 2.82% and 2.33%, respectively. The respective 
values for EDTA were 5.32% and 4.52%, while those for scraping in pure methanol 
were 7.41% and 15.28%. 
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For cell pellets a standard addition experiment was carried out using three spike 
levels (n=3). Figure 10 shows the results of the standard addition experiment (A) and 
the corresponding recovery of the internal standard (B).  
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Figure 10: Arithmetic means and standard deviations of intracellular amount of MTA (A) and 
internal standard recovery (B) in standard addition experiments employing pellets of 200,000 
Mel Im cells each. 
Spike recoveries ranged from 70.44 to 81.87% and from 66.13% to 68.65% for EDTA 
and trypsination, respectively. Interestingly, the recovery of the internal standard was 
Intra ellular IS recov ry B 
A Intracel s  addition 
Addition level [p ol]
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between 95 – 97% for cells removed with EDTA, but only 75% for trypsinated cells. 
No significant difference in extracted MTA amount could be observed. The RSDs of 
the absolute MTA peak areas ranged from 0.6 – 3.7% and 0.2 – 0.9% for cells 
treated with EDTA and trypsin/EDTA, respectively. 
Based on these results, trypsination was used in all subsequent experiments for cell 
detachment and the extraction of MTA from cell pellets was performed using pure 
methanol. 
During sample analysis, quality controls (QC’s) were measured after every 10 – 15 
biological samples. The QC was 25 nM of MTA spiked with stable isotope labeled 
MTA. The calibration check samples yielded accuracy values of approximately 96%, 
and the recovery of the internal standard was about 97% in all QC’s. The measured 
blanks (pure water) did not show MTA or internal standard. 
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3.3.2 Methylthioadenosine phosphorylase activity in fetal calf serum and 
stability of 5’-deoxy-5’-methylthioadenosine 
In 1984, Riscoe et al. [72] observed MTAP activity in both native and heat-inactivated 
human and fetal calf serum (FCS). To investigate potential degradation of MTA 
during cell culture experiments, cell culture media with and without FCS were spiked 
with an MTA standard (with a final concentration of 300 nM) and incubated for 24 h at 
37°C, to check for MTAP activity in FCS. To determine a potentially time-dependent 
decrease in the MTA concentration, samples were taken in triplicate at 0, 8 and 24 h. 
Figure 11 shows the concentration of MTA in both experiments.  
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Figure 11: Stability of MTA in cell culture medium (DMEM) with and without FCS over 24 h at 
37°C. Arithmetic means and standard deviations of MTA are shown at 0h, 8h and 24h        
(DMEM – DMEM without FCS; FCS – DMEM with FCS). 
No significant change (p=0.96) in the MTA concentration was observed in the 
presence or absence of FCS, thus demonstrating that there is no significant MTAP 
activity in FCS, and that MTA is stable over 24 h at 37°C. 
 - 36 - 
3.3.3 5’-Deoxy-5’-methylthioadenosine and melanoma cell lines 
To measure the extracellular accumulation of MTA, 200,000 cells each of the 
parental Mel Im cell line were seeded in triplicate and cultured in 2 mL DMEM for 0, 
2, 4, 6, 8, 16, 24, 30, 48, 72 and 96 h, before MTA was extracted from the cell 
medium and analyzed by LC-MS/MS. Extracellular concentrations of MTA reached a 
steady-state concentration of approx. 20 nM in the first 24 h of incubation (Figure 12).  
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Figure 12: Accumulation of extracellular MTA in cell culture medium over time by culturing 
200,000 cells in 2 mL DMEM for different time spans. 
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As a first test of the hypothesis that cells lacking MTAP do not metabolize MTA, two 
Mel Im cell clones that either lack (Mock D) or show expression of MTAP (Clone 5) 
[6] were analyzed. The clones showed a slight, albeit significant (p=0.0086), 
difference in extracellular MTA concentrations measured in quadruplicate after 24 h 
of incubation. The respective values for Mock D and Clone 5 were 11.6±0.2 nM and 
12.7±0.4 nM. Intracellular amounts of MTA, in comparison, differed significantly 
(p=0.0012) by a factor of 4 (Figure 13). These values correlated inversely with MTAP 
expression.  
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
45.00
50.00
Am
ou
nt
 M
TA
 [p
m
ol
]
Mock D
Clone 5
 
Figure 13: Absolute amount of intracellular MTA in 200,000 cells of two different Mel Im clones, 
which either lack (Mock D) or show expression of MTAP (Clone 5). 
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3.3.4 5’-Deoxy-5’-methylthioadenosine in malignant melanoma tumors 
MTA was also analyzed in biopsies of malignant melanoma (n=5) and normal skin 
(n=3). Compared to the normal skin, MTA accumulated significantly (p=0.0016) in the 
malignant melanoma by a factor of 100 (Figure 14) due to the assumed lack of 
MTAP. 
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00
M
TA
 [p
m
ol
/m
g]
Melanoma
normal Skin
 
Figure 14: MTA concentration in biopsies of malignant melanoma (n=5) and normal skin (n=3) 
corrected for weight of the biopsy samples. 
The mean concentration (±S.D.) of MTA in malignant melanoma was 6.869±2.095 
pmol/mg tissue whereas that in normal skin was 0.064±0.018 pmol/mg. Biological 
variation explains the observed relative standard deviation of approximately 30%. 
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3.3.5 5’-Deoxy-5’-methylthioadenosine in the supernatant of different 
primary cells and tumor cell lines 
Next, the concentration of MTA in cell culture media specimens of different tumor cell 
lines was determined. Figure 15 shows the concentrations of MTA in the cell culture 
media investigated after incubation for 24 h. 
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Figure 15: Concentration of MTA in cell culture media of different primary cells and tumor cell 
lines after incubation over 24 h (Lower graphic is a zoom-in of the upper graphic). 
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For most of the cell lines the MTA concentration in the medium after 24 h ranged 
between 3 and 15 nM. Interestingly, some cell lines excreted large amounts of MTA 
into the cell culture medium, including the glioblastoma cell line U87, the human T-
cell leukemia cell line Jurkat, the human acute monocytic leukemia cell line THP-1, 
one bladder (RT4) and two out of the three investigated renal carcinoma cell lines. 
This results showed, that secretion of MTA into the cell culture medium was cell line 
specific and not cell type specific and it supports the hypothesis, that the excretion of 
MTA is somehow a controlled process and not driven by a concentration gradient. 
This hypothesis is supported by Hoffman et al. who demonstrated an unidirectional 
transport mechanism of SAH, the thioether metabolite of SAM [73] and furthermore 
by the corresponding intracellular MTA concentrations (Figure 16). 
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Figure 16: Intracellular concentration of MTA in cell pellets of different tumor cell lines after 
incubation over 24 h. 
It is clearly visible, that the difference in the intracellular concentration is not as big as 
observed for the concentration in the cell culture medium. The three melanoma cell 
lines had a big difference in intracellular MTA concentration (234 vs. 61 vs. 10 
pmol/mio cells) but showed all nearly the same MTA concentration in cell culture 
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medium of approximately 5 nM. The other way round was observed for the renal 
carcinoma cell lines, they showed nearly identical intracellular MTA concentrations of 
60 nmol/mio cells but large difference in the MTA concentration in the cell culture 
medium (770 vs. 1170 vs. 8 nM). For the renal carcinoma cell lines Dr. Katrin Singer 
could show in her dissertation an inverse correlation of MTAP expression and MTA 
secretion to the cell culture media [74], i.e. the cell lines RCL 1503 and RH 556 have 
nearly no MTAP expression and therefore they excreted high amounts of MTA while 
the cell line RJ 494 show a slight MTAP expression and excreted nearly no MTA to 
the cell culture medium. These findings support the hypothesis that MTAP lacking 
cells accumulate and/or excrete MTA instead of metabolizing it [9]. 
Finally, CD8 T cells (not activated) and monocytes show no MTA secretion and only 
the monocytes had a very low intracellular MTA concentration. Both are primary cells 
and such cells are nearly not able to proliferate. In cell culture these cells can only be 
cultivated up to a few days [75]. Since polyamines and therefore also MTA were 
formed during cell proliferation, MTA is nearly not produced in this two primary cells 
and therefore consequently also not excreted to the cell culture medium. 
 
3.4 Conclusions 
An LC-ESI-MS/MS method was developed for the quantitative determination of MTA 
in cell culture media and cell pellets. The method was sensitive, precise and accurate 
in the concentration range of 2 nM – 1 µM. The LOD was determined at 62.5 pM. The 
method is reproducible with an RSD of triplicate injections of 1 – 7% in cell media and 
0.2 – 3.7% in cell extracts, while biological reproducibility ranges from 2.1 – 32.6% in 
cell culture media and 3.5 – 31.4% in cell extracts. All quality controls showed an 
accuracy of 95 – 97% with an internal standard recovery of 97%. 
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An in vivo and in vitro accumulation of MTA in MTAP lacking samples could be 
demonstrated by cell culture experiments and analysis of real tumor samples. 
The method developed will prove essential in the elucidation of utility of MTA as a 
diagnostic and/or prognostic tumor marker. 
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4. Quantitative analysis of the methionine and polyamine 
pathways 
4.1 Introduction 
To elucidate changes in the concentrations of intermediates of the methionine and 
polyamine pathways caused by a loss of MTAP activity, the method described in 
chapter 3 was expanded to all key metabolites of these pathways and liquid 
chromatography coupled to tandem mass spectrometry was chosen again as the 
analytical tool. Both extraction and separation had to be optimized. Stable isotope-
labeled standards were used to correct for extraction, separation and ionization 
problems. A shortened version of this chapter was published in the Journal of 
Chromatography A [55] and parts of the results were also shown in [76]. 
 
4.2 Experimental 
4.2.1 Chemicals 
Solvents for sample preparation and LC-MS analysis were HPLC grade and 
purchased from Fisher-Scientific (Schwerte, Germany) and Merck (Darmstadt, 
Germany). Heptafluorobutyric acid (HFBA), adenine, homocysteine, methionine, 
putrescine, and spermidine were from Fluka (Taufenkirchen, Germany), while 
adenosine, 5'-deoxy-5'-(methylthio)adenosine, ornithine, S-adenosyl-L-homocysteine, 
S-adenosyl-methionine, spermine, acetylputrescine, N8-acetylspermidine, 
acetylspermine, Tris(2-carboxyethyl) phosphine hydrochloride (TCEP), U-13C4-
putrescine, and butane-d8-spermine were from Sigma Aldrich (Taufenkirchen, 
Germany). N1-acetylspermidine was from Wako Chemicals (Neuss, Germany), U-
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13C5-adenine from Hartmann-Analytic (Braunschweig, Germany), [1’,2’,3’,4’,5’-13C5]-
adenosine from Omicron Biochemicals (South Bend, IN, USA), d7-ornithine from 
Cambridge Isotope Laboratories (Andover, MA, USA), and d3-S-adenosylmethionine 
and 3,3,3’,3′,4,4,4′4′-d8-homocystine from CDN-Isotopes (Pointe-Claire, Quebec, 
Canada). [1’,2’,3’,4’,5’-13C5]-MTA was prepared in house according to Robins et al. 
[69] (see chapter 3.2.2), while U-15N3-spermidine was provided by Keijiro Samejima, 
Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan, 
who had synthesized it according to Hara et al. [77]. The water used was purified by 
means of a PURELAB Plus system (ELGA LabWater, Celle, Germany). 
 
4.2.2 Internal standard preparation and stock solutions 
A stock solution of each stable-isotope labeled standard was prepared in aqueous 
0.1 M acetic acid. The stable-isotope labeled standards were combined in a working 
solution containing 1 µM [1’,2’,3’,4’,5’-13C5]-MTA, 1µM [1’,2’,3’,4’,5’-13C5]-adenosine, 
5 µM d7-ornithine, 5 µM d3-SAM, 5µM U-13C5-adenine, 10µM 15N3-spermidine, 10 µM 
U-13C4-putrescine and 10 µM d8-spermine, respectively. The final concentrations of 
the internal standards spiked into samples and calibration standards were 100 nM, 
500 nM, and 1 µM, respectively. The addition of acetic acid had been reported to 
diminish the decomposition of SAM [78]. 
A standard solution of stable-isotope labeled homocysteine was obtained by reducing 
32.1 mg of d8-homocystine in 10 mL of a solution of 121 mg/mL TCEP in water. The 
resulting d4-homocysteine concentration was 23.26 mM and the solution was diluted 
with 0.1 M acetic acid to a working concentration of 10 µM. The final concentration of 
d4-homocysteine spiked into samples and standards was 1 µM. 
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Stock solutions of unlabeled standards were prepared in aqueous 0.1 M acetic acid 
and serially diluted over a concentration range of 500 µM to 0.5 nM. Spiking with 
internal standard was performed immediately before calibration. For calibration, 10 
µL of each internal standard solution were transferred into a 0.2-mL micro-insert 
(VWR, Darmstadt, Germany) in a 1.5-mL glass vial (Fisher-Scientific), dried by 
evaporation using an infrared vortex-vacuum evaporator (CombiDancer, Hettich AG, 
Bäch, Switzerland), and then reconstituted with 100 µL of the respective aqueous 
standard. To avoid detector saturation, injection volumes of solutions containing 
between 7.5 µM and less than 75 µM of each standard were reduced from 10 to 2 
µL, and halved again for standard solutions of ≥ 75 µM. 
 
4.2.3 Cell culture and cell harvesting 
The human hepatocellular carcinoma (HCC) cell line PLC (CRL-8024) [5] and the 
melanoma cell lines Mel Im and HTZ-19 [12,70] were grown at 37°C and 5% (PLC) 
and 8% (Mel Im and HTZ) CO2, respectively, in Dulbecco's modified Eagle medium 
(DMEM; PAN Biotech GmbH, Aidenbach, Germany), which had been supplemented 
with penicillin (400 U/mL), streptomycin (50 µg/mL), L-glutamine (300 µg/mL), and 
10% fetal calf serum (FCS; Sigma, Deisenhofen, Germany). 
The adherently growing melanoma cells were cultured in six-well plates (Corning, 
NY, USA) and detached with 200 µL of 0.05% (w/v) trypsin and 0.02% (w/v) EDTA in 
Hanks’ balanced salt solution (Sigma-Aldrich). Trypsination was stopped after 5 min 
by the addition of 700 µL of cell culture medium. Following centrifugation at 100xg (5 
min, room temperature), the supernatant was removed. The cell pellet was washed 
with PBS buffer, centrifuged again (100xg, 5 min, room temperature), and the cell 
pellets were then stored at -80°C until extraction. 
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The adherently growing HCC cells were cultured in Corning 25cm2 culture flasks 
(Corning) and harvested by trypsination using 2 mL trypsin solution as described 
above. Following centrifugation of detached cells at 700xg (5 min, 4°C), the 
supernatant was removed. The cell pellet was washed with PBS buffer, centrifuged 
(700xg, 5 min, 4°C), and then shock-frozen in liquid nitrogen and stored at -80°C until 
extraction. 
The experimental work described in chapter 4.2.3 was done by Georgi Kirovski 
(HCC-cell line) and Susanne Wallner (melanoma cell lines), respectively, in the 
working groups of PD Dr. Claus Hellerbrand (Department of Internal Medicine I, 
University Hospital Regensburg) and Prof. Anja Bosserhoff (Institute of Pathology, 
University of Regensburg). 
 
4.2.4 Analyte extraction from the pellets and spiking experiment 
Metabolites are commonly extracted from cells and tissues with methanol (MeOH)/ 
water at a ratio of 80:20. To verify that 80:20 MeOH/water was also best suited for 
extracting metabolites of the methionine and polyamine pathways, different solvent 
combinations (pure MeOH, MeOH/0.1 M acetic acid 80:20 v/v, and MeOH/0.1 M 
acetic acid 50:50 v/v) were tested. Briefly, 600 µL of the different solvents were 
added to the frozen pellets and internal standard was spiked as described above. 
Then the sample was slowly thawed on ice. To complete the cell lysis, the cells were 
again shock-frozen in liquid nitrogen and thawed on ice. The freeze/thaw cycle was 
performed three times and the sample was vortexed between each cycles. The 
sample was centrifuged at 9,000xg for 5 min at 4°C and the supernatant was 
transferred to a 1.5-mL glass vial. The pellet was washed twice with 200 µL of 
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solvent and all supernatants were combined. The solvent was evaporated and the 
residues were reconstituted in 100 µL of aqueous 0.1 M acetic acid. 
For cell pellets a spiking experiment was carried out to evaluate extraction efficiency 
and matrix effects. Prior to extraction, the cell pellets were spiked in quadruplicate 
with three different concentration levels and extracted as described above. The 
spiking concentrations were individually selected for each analyte based on the 
intracellular analyte concentration x (spike levels x/2, x, 2x) and extracted as 
described above.  
 
4.2.5 Preparation of hepatic tissue samples 
Hepatocellular carcinoma tissue samples and normal liver specimens were 
ascertained from patients undergoing partial hepatectomy. Informed consent had 
been obtained from all patients following approval of the study by the local Ethics 
Committee. These samples were obtained by PD Dr. Claus Hellerbrand from the 
Department of Internal Medicine I, University of Regensburg. 
Tissue samples were weighted and homogenized in 600 µL of MeOH/0.1 M acetic 
acid (80:20, v/v) using “Precelly-Keramik-Kit 1.4 mm” vials (Peqlab Biotechnologie 
GmbH, Erlangen, Germany). The samples were homogenized twice at 5,500 rpm for 
15 s with an intermediate 30-s pause (Peqlab Biotechnologie GmbH). Samples were 
centrifuged at 9,000xg for 5 min at 4°C, and the supernatant transferred to a 1.5-mL 
glass vial. The pellet was washed twice with 200 µL of the solvent, homogenized 
again, and all supernatants were combined. After solvent evaporation, the residues 
were reconstituted in 100 µL of 0.1 M acetic acid. 
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4.2.6 Hepatic tissue samples of mice with non-alcoholic steatohepatitis 
and liver cirrhosis 
Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of fat 
in the liver in the absence of excessive alcohol abuse. It is typically related to insulin 
resistance and the so-called metabolic syndrome, the clinical manifestations of which 
include obesity, hyperlipidemia, diabetes mellitus type II, and high blood pressure. 
Non alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD and 
regarded a major cause of liver cirrhosis [79]. To initiate the development of NASH, 
mice were fed a so-called Paigen diet containing 15% lard / cocoa butter, 1.25 % 
cholesterol and 0.5% sodium cholate over 30 weeks. This protocol was modified from 
[80,81]. The mice were sacrificed; the liver was resected and immediately frozen in 
liquid nitrogen and stored at -80°C until further sample preparation as described 
above.  
Liver cirrhosis was induced by repeated intraperitoneal injection of CCl4 (1 µL/g body 
weight) and the animals were sacrificed after three days [82]. The removed liver was 
immediately frozen with liquid nitrogen and stored at -80°C until further sample 
preparation as described above. 
The experimental work described in chapter 4.2.6 was performed by coworkers of PD 
Dr. Claus Hellerbrand at the Department of Internal Medicine I, University of 
Regensburg. 
 
4.2.7 Mice glioma tissue 
The used brain tumor model was described previously by Grauer et al. [83] and the 
experimental work described in chapter 4.2.7 was carried Dr. Oliver Grauer 
(Department of Neurology, University of Regensburg). Briefly, to induce tumors mice 
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glioma cells (GL261) were harvested washed and the cell count was adjusted. A total 
of 100,000 cells were injected below the dura mater into the right cerebral 
hemisphere. Animals were observed daily and sacrificed after the occurrence of 
characteristic symptoms, such as hunched posture, reduced mobility and significant 
weight loss (>20%). The animals were perfused with 0.9 % NaCl solution and the 
tumor as well as the surrounding brain parenchyma resected. As a control the normal 
brain parenchyma from the tumor free left brain region was taken. Tissue samples 
were shock-frozen in liquid nitrogen and stored at -80°C until extraction. The further 
preparation was carried out as described in 4.2.5. 
 
4.2.8 Renal carcinoma tissues 
Renal carcinoma tissue samples and non-cancerous tissue specimens were 
ascertained from patients undergoing nephrectomy. Informed consent had been 
obtained from all patients following approval of the study by the local Ethics 
Committee. Samples were stored at -80°C until further preparation as described for 
hepatic tissue samples. 
These samples were provided by Prof. Anja Bosserhoff from the Institute of 
Pathology, University of Regensburg. 
 
4.2.9 Instrumentation 
Liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-
MS/MS) was performed using an Agilent 1200 SL HPLC system (Böblingen, 
Germany) and a PE Sciex API 4000 QTrap mass spectrometer (Applied Biosystems, 
Darmstadt, Germany) equipped with a turbo ion spray source (completely controlled 
by Analyst version 1.5). The column oven was kept at 25°C. An Atlantis T3 3µm (2.1 
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i.d. x 150 mm) reversed phase column (Waters, Eschborn, Germany) was used. LC 
separation was carried out using a mobile phase consisting of 0.1% acetic acid and 
0.025% HFBA in water (Solvent A), respectively in acetonitrile (Solvent B). The 
gradient employed was as follows: 0-4 min linear increase from 0% to 30% B, 4-8 
min from 30% to 40% B, 8-8.1 min 40% to 100% B and hold at 100% B for 5 min. 
The flow-rate was 400 µL/min. If not otherwise noted, sample volumes of 10 µL were 
injected. 
The API 4000 QTrap mass spectrometer was operated in positive mode using turbo 
ion spray with gas 1, gas 2, and curtain gas set at 50, 30, and 10 psi, respectively. 
The source was heated to 500°C. Quantitative determination was performed with 
multiple-reaction monitoring (MRM) using the parameters listed in Table 3. 
Table 3: List of chromatographic retention time (RT), selected MRM parameters, loss off, 
declustering potential (DP), collision energy (CE), and collision cell exit potential (CXP) for 
each metabolite measured. 
Analyte RT [min] 
Q1 
mass 
Q3 
mass Loss off DP CE CXP 
Adenine 5.70 135.9 119.1 - NH3 76 33 8 
Adenine-13C5 5.70 140.9 124.1 - NH3 76 33 8 
Adenosine 5.89 268.2 136.1 - sugar moiety 36 24 9 
Adenosine-13C5 5.89 273.2 136.1 - 13C5-sugar moiety 36 24 9 
Homocysteine 2.96 136.2 90.1 - formic acid 31 17 6 
Homocysteine-d4 2.96 140.2 94.1 - formic acid 31 17 6 
MTA 6.98 298.2 136.1 - sugar moiety 60 19 9 
MTA-13C5 6.98 303.2 136.1 - 13C5-sugar moiety 60 19 9 
Ornithine 2.31 133.3 116.1 - NH3 44 13 9 
Ornithine-d7 2.31 140.3 123.1 - NH3 44 13 9 
Putrescine 5.92 89.1 72.1 - NH3 36 17 4 
Putrescine-13C4 5.92 93.1 76.1 - NH3 36 17 4 
Acetylputrescine 5.32 131.2 72.1 - NH2COCH3 6 23 2 
SAH 6.34 385.2 136.1 - sugar moiety 56 27 10 
SAM 6.51 399.1 136.1 - sugar moiety 66 37 8 
SAM-d3 6.51 402.1 136.1 - d3-sugar moiety 66 37 8 
Spermidine 7.19 146.2 72.1 - NH2(CH2)3NH2 51 21 4 
Spermidine-15N3 7.19 149.2 73.1 - 15NH2(CH2)315NH2 51 21 4 
N1-Acetylspermidine 6.70 188.3 100.1 - NH2(CH2)4NH2 51 27 6 
N8-Acetylspermidine 6.76 188.3 114.1 - NH2(CH2)3NH2 51 27 6 
Spermine 7.48 203.2 112.1 - [ NH2(CH2)3NH2 + NH3] 66 27 8 
Spermine-d8 7.48 211.2 120.1 - [ NH2(CH2)3NH2 + NH3] 66 27 8 
Acetylspermine 7.30 245.3 100.1 - NH2(CH2)3NH(CH2)4NH2 61 31 6 
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The electron multiplier was set at 2100 V. All MS parameters were optimized by 
direct infusion, the source parameters by flow injection. Data analysis was performed 
by Analyst version 1.5.1. 
 
4.2.10 Data analysis 
Standard calibration curves were plotted as the chromatographic peak area ratio 
(analyte / IS) versus the corresponding nominal concentration ratio (analyte / IS). A 
1/x weighted regression analysis was used to determine the slope, intercept and 
coefficient of determination (r2). An unpaired two tailed t-test was used to determine 
whether the means of analyte concentrations were significantly different (p < 0.05). 
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4.3 Results and Discussion 
4.3.1 Chromatographic Optimization and Calibration 
As mentioned in the introduction, this method is an expansion of the method 
described in chapter 3. Chromatographic separation was tried at first with the 
solvents and the gradient of the previous method. Figure 17 clearly indicates that the 
solvents and gradient of this method are insufficient to separate all analytes. 
 
Figure 17: Chromatographic separation of a subset of the metabolites of the methionine and 
polyamine pathways. Chromatographic conditions from the method described in chapter 3 
were used. 
To achieve a higher retention of the polar analytes 0.025% HFBA were added to both 
solvents and the linear gradient was replaced by a stepwise gradient. Figure 18 
shows a representative chromatogram of intermediates of the methionine and 
polyamine metabolism detected in an extract of a liver biopsy specimen. The method 
development started with a smaller set of analytes and was expanded over time. 
Therefore, more analytes are shown in Figure 18 than in Figure 17. 
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Figure 18: Chromatogram of intermediates of the methionine and polyamine pathways in an 
acidified methanolic extract of a liver tumor biopsy (Ac - Acetyl, Spd – Spermidine, Spm – 
Spermine). Chromatography was optimized to the parameters mentioned in chapter 4.2.9. 
For absolute quantitative analysis, a calibration was carried out for all analytes in the 
range of 0.5 nM to 500 µM. Table 4 lists the calibration parameters obtained 
according to the FDA guidelines for bioanalytical method validation [71]. A general 
1/x-weighting factor was used. 
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Table 4: Calibration parameters. Analytes printed in bold were quantified using the 
corresponding stable-isotope labeled compound (acetylated polyamines were quantified using 
the unacetylated analog, SAH using d3-SAM). 
Analyte LODa [nM] Linear range [nM] (LLOQb – ULOQc) Slope Intercept 
Coefficient of 
determination 
(r2) 
Adenine 2.5 5.0 – 500,000 1.230 0.28600 0.9986 
Adenosine 2.5 5.0 – 100,000 0.713 0.04630 0.9975 
Homocysteine 2.5 7.5 – 250,000 1.120 0.00636 0.9989 
MTA 2.5 5.0 – 100,000 0.670 0.04430 0.9963 
Ornithine 25.0 50 – 500,000 1.120 0.07950 0.9959 
Putrescine 12.5 50 – 500,000 0.903 0.01090 0.9993 
Acetylputrescine 100.0 500 – 50,000 2.170 0.06350 0.9957 
SAH 12.5 25 – 10,000 1.460 0.18300 0.9980 
SAM 1.0 2.5 – 25,000 0.696 0.00270 0.9929 
Spermidine 12.5 50 – 25,000 0.845 0.04090 0.9978 
N1-Acetylspermidine 25.0 50 – 2,500 1.530 0.04500 0.9921 
N8-Acetylspermidine 1.0 2.5 – 500 2.640 0.00697 0.9979 
Spermine 12.5 25 – 100,000 1.610 0.04340 0.9963 
Acetylspermine 2.5 5.0 – 100,000 1.730 0.00437 0.9992 
 a LOD, signal-to-noise ratio ≥ 3;  
b LLOQ, lowest calibration point with five times the response compared to a blank, an accuracy of 
80% – 120%, and an imprecision <20%;  
 c ULOQ, highest calibration point with an accuracy of 80% – 120% and imprecision <20%. 
Analytes, for which a matching stable-isotope labeled internal standard was available 
(printed in bold in Table 4), yielded in general lower LODs and LLOQs than the other 
analytes. The acetylated polyamines were quantified with the corresponding stable 
isotope labeled unacetylated analog, and SAH with d3-SAM. The same tendency was 
observed for the linear range. With the exception of spermidine, all the analytes with 
a matching stable-isotope labeled internal standard available showed a linear range 
over three to five orders of magnitude. In contrast, the acetylated polyamines and 
SAH showed linearity only over two to three orders of magnitude, emphasizing the 
need for stable-isotope labeled internal standards to account for matrix effects. For all 
analytes the coefficient of determination (r2) exceeded 0.99. The average 
repeatability of triplicate injections was 2.38%. 
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4.3.2 Extraction optimization for cell pellets 
Three different methanol/water combinations (50% MeOH, 80% MeOH and 100% 
MeOH) were tested to determine the solvent that gave the highest extraction yield of 
the metabolites under investigation. Figure 19 shows the extracted amounts of 
analytes and Figure 20 the recovery of the internal standard using the different 
solvent combinations. 
Extracted Amounts of Metabolites normalized to 80% MeOH
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Figure 19: Effect of 50% aqueous methanol and pure methanol on the extraction efficiency of 
intermediates of the methionine and polyamine pathways in relation to the area integrals 
measured at 80% methanol (set at 1). 
The data presented in Figure 19 were normalized to data obtained using 80% MeOH 
for better comparability, because the intracellular concentrations of the metabolites 
differed over three to four orders of magnitude. With this normalization all analytes 
could be displayed in one diagram. Except for acetylputrescine, SAH and MTA, the 
extracted amount increased with the water content of the extraction solvent. For 
adenine, adenosine and spermine the highest yields were obtained with 50% MeOH. 
The remaining analytes did not show great differences in extraction yield between 
50% and 80% methanol. 
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Figure 20: Percent recovery of internal standards at different concentrations of methanol 
employed for extraction. 
For six of nine internal standards, 80% methanol yielded similar or even higher 
recoveries than 50% methanol (Figure 20). Moreover, 80% methanol resulted in 
improved protein precipitation, and thus, provided “cleaner” extracts and facilitated 
the retrieval of supernatant liquid. Consequently, 80% methanol was used for all 
further extractions. To stabilize SAM, acetic acid was added at a final concentration 
of 0.1 M. This resulted also in higher extraction yields for spermidine and spermine 
without affecting the extraction behavior of the other metabolites (data not shown). 
 - 57 - 
4.3.3 Spiking experiment 
The recovery of metabolites from Mel Im cell pellets was determined at three different 
spiking levels (Figure 21).  
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Figure 21: Recovery of analytes in the spike-in experiment. 
Most of the analytes yielded spike recoveries exceeding 80%. One of the exceptions 
was homocysteine, the recoveries of which ranged from 46% to 83% despite the 
availability of a stable-isotope labeled internal standard generated by the reduction of 
deuterated homocystine with TCEP prior to its addition to the cell pellet. An 
explanation for the low recoveries of homocysteine spiked to biological samples 
might be, that it bound to other thiols in the sample via the formation of covalent 
disulfide bonds [84], which would result in non-optimal correction for inter-sample 
differences in extraction and ionization efficiency. Attempts to measure total instead 
of free homocysteine only by the reduction of the disulfide bond between 
homocysteine and other thiols or sample proteins before analysis by the addition of 
TCEP to the cell extracts showed a significant at least tenfold increase in peak area 
for homocysteine. However, the addition of TCEP also exerted a detrimental effect on 
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chromatography shifting the retention of most analytes into the void volume (data not 
shown). Low recoveries were also seen for adenine, likely due to the fact that its 
intracellular concentrations were close to the LLOQ of the method. For the acetylated 
polyamines, the corresponding non-acetylated polyamines were used to account for 
inter-sample differences in extraction and ionization efficiency. This might explain the 
lower recovery (60-80%) and higher RSD (15-25%) values for these analytes. 
 
4.3.4 Tumor cell lines 
The molar amounts of intermediates of the methionine and polyamine metabolism 
determined in two different melanoma cell lines, namely HTZ-19 and Mel Im, and the 
HCC cell line PLC are listed in Table 5. All values are given in nmol/million cells. 
Table 5: Molar amounts of intermediates of the methionine and polyamine pathways 
determined in four replicate methanol:water (80:20, v/v) extracts each for the melanoma cell 
lines HTZ-19 and Mel Im, as well as the hepatoma cell line PLC. Analytes printed in bold were 
quantified using the internal standard quantification trace of the corresponding stable-isotope 
labeled compound. 
 HTZ-19 Mel Im PLC 
 Mean 
nmol/mio 
cells 
S.D. Mean 
nmol/mio 
cells 
S.D. Mean 
nmol/mio 
cells 
S.D. 
Adenine 3.74 0.48 5.24 0.86 296.15 62.15 
Adenosine 209.25 26.59 223.00 18.51 87.02 88.80 
Homocysteine 5.43 0.88 4.66 0.93 5.93 0.79 
MTA 18.35 1.44 16.90 0.71 25.39 2.69 
Ornithine 896.75 155.59 507.50 148.81 351.40 40.75 
Putrescine 641.75 52.54 875.00 9.97 1761.07 338.23 
Acetylputrescine 13.88 1.31 27.68 4.74 67.54 10.62 
SAH 108.15 11.45 82.60 2.73 15.19 3.38 
SAM 1162.50 86.17 942.50 15.33 939.39 178.57 
Spermidine 3487.50 233.43 2727.50 401.86 7354.31 1241.14 
N1-Acetylspermidine 734.00 61.81 496.00 9.83 134.03 35.09 
N8-Acetylspermidine 5.67 0.60 4.83 1.46 4.07 1.04 
Spermine 2487.50 189.98 2487.50 80.98 7162.00 1041.83 
Acetylspermine 935.00 216.59 1427.50 172.51 35.36 9.20 
The most abundant metabolites in the melanoma cell lines were spermidine, 
spermine, acetylspermine, and SAM, the molar amounts of which ranged from 
approximately 0.9 to 3.5 µmol per million cells. Spermidine and spermine were also 
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the most abundant metabolites in the HCC cell line PLC, with molar amounts as high 
as 7.35±1.24 and 7.16±1.04 µmol per million cells. The third most abundant 
metabolite in PLC cells was putrescine (1.76±0.33 µmol/million cells), which was 
found at concentrations about two- to three-fold higher than in the melanoma cell 
lines. The concentration of SAM in PLC cells was similar to that observed in the 
melanoma cell lines. The least abundant metabolites in the three cancer cell lines 
were homocysteine (4.66±0.93 - 5.93±0.79 nmol/million cells) and                     
N8-acetylspermidine (4.07±0.93 - 5.67±0.60 nmol/million cells). Interestingly, the 
molar amount of adenine observed in PLC cells was 56- to 79-fold greater than in the 
melanoma cell lines. A detailed explanation of the partly significant differences in 
metabolite concentrations observed among the cell lines will have to await 
measurements of the abundance and activity of the enzymes involved in the 
methionine and polyamine pathways. 
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4.3.5 Liver tissue 
Metabolite concentrations observed in vitro might differ significantly from those found 
in vivo. To account for such differences we also analyzed 80% methanol extracts of 
seven human hepatocellular carcinoma (HCC) and three normal liver tissue 
specimens. As in the HCC cell line PLC, spermidine and spermine were among the 
most abundant metabolites (Table 6). 
Table 6: Metabolite concentrations in human hepatocellular carcinoma (n=7) and normal liver 
tissue (n=3) biopsy specimens. Analytes printed in bold were quantified using the internal 
standard quantification trace of the corresponding stable-isotope labeled compound. 
 Carcinoma (n=7) Normal (n=3) 
 Mean [pmol/mg] S.D. [pmol/mg] Mean [pmol/mg] S.D. [pmol/mg]
Adenine 4.42 2.65 3.94 1.57 
Adenosine 21.44 11.02 55.87 37.59 
Homocysteine 0.34 0.16 0.91 0.77 
MTA 2.84 2.52 1.31 0.38 
Ornithine 559.72 281.04 497.30 158.60 
Putrescine 163.92 108.39 83.85 29.76 
Acetylputrescine 44.53 14.35 106.72 66.14 
SAH 43.94 23.44 55.51 8.96 
SAM 74.51 60.67 38.00 11.77 
Spermidine 458.82 246.24 317.36 107.57 
N1-Acetyspermidine 15.94 3.44 36.04 44.76 
N8-Acetylspermidine 1.09 0.63 1.39 0.92 
Spermine 602.29 140.78 647.32 76.96 
Acetylspermine 14.91 2.96 23.45 29.35 
While the average molar ratios of spermidine and spermine to putrescine in PLC cells 
(4.2 and 4.1, respectively) and the tumor biopsies (2.8 and 3.7, respectively) were 
quite similar, the molar amount of ornithine, relative to spermidine and spermine, 
determined in the tumor biopsies was about 20-fold greater than in the PLC cells. 
Finally, the molar amount of adenine observed in the tumor biopsies was 
comparatively much lower than in the PLC cells. 
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Figure 22 shows the normalized concentrations of the methionine metabolites and 
polyamines measured in the HCC and normal liver tissue biopsy specimens. 
 
Figure 22: Metabolite concentrations (pmol/mg tissue) in seven hepatocellular carcinoma 
specimens normalized to tissue specimens from normal liver (n=3). Depicted are arithmetic 
means and standard deviations. * p<0.05; ** p<0.01 
As expected, the average concentration of MTA in tumor exceeded significantly the 
MTA level in normal tissue presumably due to the reported lack of MTAP in the 
former [5]. Similar increases in concentration were observed for SAM and putrescine. 
This indicates that accumulated MTA reduces the metabolism of SAM and putrescine 
via a feedback loop. The elevated level of spermidine is an indication for a higher cell 
proliferation in tumors [85-88] and together with the nearly constant spermine level it 
is suggested that the metabolism of SAM and putrescine in only partly reduced, in 
case of a total inhibition of this reaction, a decrease in the polyamines is expected. 
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4.3.6 Non-alcoholic steatohepatitis 
Figure 23 shows the normalized concentrations of the methionine metabolites and 
polyamines measured in the liver of mice with and without non-alcoholic 
steatohepatitis (NASH). Absolute concentrations are listed in Table A 1 in the 
appendix. 
 
Figure 23: Metabolite concentrations (pmol/mg tissue) in fatty livers normalized to tissue 
specimens from healthy liver (n=5). Depicted are arithmetic means and standard deviations.     
* p<0.05; ** p<0.01 
Significant changes in the profile of methionine and polyamine metabolites could be 
observed. As observed in human liver, the most abundant metabolites were ornithine 
(6223 vs. 5125 nmol/g), spermidine (665 vs. 380 nmol/g) and spermine (526 vs. 146 
nmol/g). The highest increases except for N-acetyl-putrescine (0.01 vs. 0.07 nmol/g) 
were observed for putrescine, MTA and SAM (3.0-, 2.6- and 1.6-fold). The liver of 
NASH mice has a high percentage of fat and, therefore, the cell count per mg total 
tissue weight is lower compared to healthy liver. The increase of MTA, putrescine 
and SAM together with the decrease of spermidine and spermine indicates that the 
overall MTAP activity in NASH mice is reduced. The reason for the decreased overall 
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MTAP activity could be a lower expression, a lower MTAP concentration caused by 
the incubated fat or an inhibition of the enzymatic activity. 
 
4.3.7 Liver cirrhosis 
Figure 24 shows the normalized concentrations of the methionine metabolites and 
polyamines measured in the liver of mice with and without CCl4 induced liver 
cirrhosis. Absolute concentrations are listed in Table A 2 in the appendix. The 
acetylated polyamine levels are missing, because the samples were measured 
before inclusion of these analytes in the method. 
 
Figure 24: Metabolite concentrations (pmol/mg tissue) in liver cirrhosis normalized to tissue 
specimens from healthy liver (n=3). Depicted are arithmetic means and standard deviations.     
* p<0.05; ** p<0.01 
Changes during cirrhosis are mainly observed in the concentrations of MTA, 
putrescine and SAM. The increase is much more intensive than in NASH, probably 
due to more severe liver tissue damage than in the NASH model. It was also 
observed by Berasain et al [89] that MTAP expression in cirrhosis is much lower than 
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in tumors as well as in healthy liver. Hence, the accumulation of MTA was likely 
caused by a decrease in MTAP expression/activity. The significantly lower level of 
spermine might be explained with the inhibitory effect of MTA on spermine synthase. 
As observed by Hibasami et al. [90], MTA has a stronger inhibitory effect on 
spermine synthase (50% inhibition at 10-15 µM MTA) than spermidine synthase 
(50% inhibition at 30-45 µM MTA). The lower concentrations of ornithine could be 
caused by a higher activity of ornithine decarboxylase [91,92], another reason for the 
elevated putrescine concentration. 
 
4.3.8 Brain tumor samples 
Mice glioma tissue samples were analyzed to examine changes in the methionine 
and polyamine pathways in another tumor. As expected, MTA increases highly 
significant in the tumor samples due to the lack of MTAP in brain tumors [93]. SAM 
and putrescine levels also increased significantly, as observed in other tumors. For 
most analytes no significant difference between the controls (left brain region) and 
the non-tumorous tissues of the right brain region could be observed. Only analytes 
with a strong (more then 10-fold) accumulation in the tumor, such as homocysteine, 
ornithine, putrescine, N1- and N8-acteyl-spermidine and acetyl-spermine, show a 
slight accumulation in the non-tumorous tissue. In case of putrescine and N1-acetyl-
spermidine this accumulation is significant. This could be caused by diffusion of the 
high concentrated metabolites out of the tumor. For the other analytes no differences 
between the left (control) and right brain parenchyma were observed, so the changes 
in the metabolite concentrations are restricted to the tumor (Figure 25). Non-
normalized values are given in Table A 3 in the appendix. 
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Figure 25: Metabolite concentrations (pmol/mg tissue) in mice glioma normalized to healthy 
brain parenchyma. Healthy control – left brain parenchyma, non tumorous tissue – right brain 
parenchyma surrounding the glioma, tumor – glioma sample. (n=4). Significances are shown 
for tumor vs. healthy control.* p<0.05; ** p<0.01 
As can be seen, homocysteine increased dramatically by a factor of 25, a behavior 
observed for the first time in tumors analyzed in this work. A possible explanation 
could be found in methylation reactions and a subsequent formation of 
homocysteine. Due to a defect of the methionine synthase (EC 2.1.1.13), 
homocysteine could not be recycled back to methionine. This hypothesis is supported 
by Fiskerstrand et al, who observed the loss of the ability to form methionine from 
homocysteine in glioma cell lines [94]. The increase of spermidine and spermine (2- 
and 2.5-fold) is an indication for a higher cell proliferation [85-88], the massive 
increase of putrescine (22-fold) is an indication for a higher ornithine decarboxylase 
(ODC) activity, supported by Subhi et al. [29], who postulated that MTA inhibits ODC 
by downstream metabolites and observed a loss of MTAP and elevated ODC in 
pancreatic cancer [95]. Since MTA is slower metabolized in the tumor, the inhibitory 
effect on ODC caused by downstream metabolites of MTA could be lower. The lower 
 - 66 - 
relative standard deviation compared to HCC is the result of the higher homogeneity 
of the sample group. Instead of different humans here a group of four inbred mice 
were used. 
 
4.3.9 Renal carcinoma 
To examine changes in the methionine and polyamine pathways in a third tumor 
species, renal carcinomas were analyzed. Figure 26 shows the normalized 
concentrations of the metabolites in the methionine and polyamine pathway 
measured in human kidney with and without renal carcinoma. Absolute 
concentrations are listed in Table A 4 in the appendix. 
 
Figure 26: Metabolite concentrations (pmol/mg tissue) in renal carcinomas normalized to tissue 
specimens from healthy kidneys (n=5). Depicted are arithmetic means and standard 
deviations.* p<0.05; ** p<0.01 
As observed in other tumors and also expected here, MTA (due to the lack of MTAP 
in tumors), SAM and putrescine are significantly increased. The acetylated putrescine 
was in all cases below the LOD. Since spermidine and spermine levels are elevated, 
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an increased polyamine synthesis is assumed, which indicates higher cell 
proliferation in the tumor [85-88]. For the first time here a nearly 2-fold increase of 
SAH was observed, in all other analyzed samples SAH stayed nearly constant. An 
explanation could be a higher methylation rate in renal carcinomas and therefore a 
higher production of SAH. Della Ragione and Pegg observed an inhibition of S-
adenosylhomocysteine hydrolase (EC 3.3.1.1) by increased levels of MTA [96]. This 
enzyme cleaves SAH to homocysteine and adenosine. Since SAH is an inhibitor of 
methylation reactions [97], the higher levels of SAH could be another reason for the 
elevated levels in SAM. Both directions for the metabolism of SAM (methylation and 
polyamine synthesis with the formation of MTA) are restricted. As observed in the 
human liver tumor samples, the standard deviation is much higher compared to all 
experiments with a mouse model. This is again caused by the higher variation of the 
different human individuals compared to laboratory mice. 
 
4.4 Conclusions 
An LC-ESI-MS/MS method was developed for the quantitative determination of 
intermediates of the methionine and polyamine pathways. With LODs and LLOQs in 
the lower nanomolar range, the method was sufficiently sensitive for the analysis of 
the intermediates in aqueous methanol extracts of cell culture samples, human liver 
biopsies and mural brain tumors. The use of stable-isotope labeled internal standards 
proved critical in achieving an analytical reproducibility of 1 - 3% and linear dynamic 
ranges over 3 - 5 orders of magnitude. The method shall prove useful in the field of 
finding diagnostic and/or prognostic tumor markers. Possible candidates are MTA, 
putrescine and SAM, which each increase in different tumors. 
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Caused by a lower overall-activity of MTAP (the reasons of the lower activity could be 
a lack of MTAP protein or a lower activity of the protein and are not discussed here) 
MTA accumulates and as a consequence of this the precursors of MTA, namely 
putrescine and SAM, do also accumulate. The decarboxylated form of SAM (dcSAM) 
and putrescine are the educts of MTA synthesis. Due to its instability it was not 
possible to quantify dcSAM. Cataldi et al. published a method, where they have 
estimated the concentrations of dcSAM using the calibration curve of SAM assuming 
a similar ionization behavior [30]. A separate calibration curve was not performed due 
to the instability of this metabolite. The accumulation of MTA, putrescine and SAM 
could be observed in all studied tumors as well as in different stages of liver damage. 
However the tumors show also special difference in the metabolite pattern, e.g. the 
tremendous increase of homocysteine in gliomas due to a deficiency in methionine 
synthase. 
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5. Determination of the activity of methylthioadenosine 
phosphorylase 
5.1 Introduction 
During the analysis of the metabolite concentrations in the methionine and polyamine 
pathways it was observed, that the concentration of MTA does not always correlate 
with MTAP protein abundance. This resulted in the hypothesis that not only protein 
concentration but also enzyme activity is an important parameter for changes in 
metabolite concentration. Consequently, an activity assay for MTAP is needed to 
elucidate, if the accumulation of MTA is caused by changes in MTAP enzyme activity.  
A few methods have been already described to analyze MTAP activity [2,4,41]. All 
these assays use a potassium phosphate buffer (concentration 20 – 50 mM, pH 7.4) 
and DTT as reducing agent. Interestingly, no cofactors were used. The reaction 
temperature was 37°C in case of human MTAP. Cells were directly lysed in the buffer 
and the MTAP activity was determined by measuring the formation of [methyl-14C]5-
methylthioribose-1-phosphate from [methyl-14C]-MTA. In the present work, the assay 
was adapted to measure MTAP activity in liver biopsies. Following the literature, the 
biopsy samples were homogenized in potassium phosphate buffer (50 mM, pH 7.4) 
and the reaction temperature was set to 37°C. In contrast to the literature, stable 
isotope labeled MTA was chosen as substrate and the turnover was determined by 
liquid chromatography-mass spectrometry. This makes the handling of this assay 
easier and safer. As reducing agent TCEP was used, because it has a non pungent 
odor and is also not volatile, and a quantitative reduction will be obtained in less than 
5 minutes of reaction. Pyridoxal phosphate was added as a cofactor although it 
should not be necessary for the enzymatic degradation of MTA. However, it is 
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planned to expand this assay to the measurement of ODC activity in the same 
reaction mixture, which requires Pyridoxal phosphate [98]. 
The assay is based on the principle of continuous reaction monitoring. Therefore, 
aliquots of the reaction mixture were taken at different time points and the reaction 
was quenched with pure MeOH. The concentration of MTA was determined by liquid 
chromatography-mass spectrometry based on the method described in chapter 4. 
The activity was calculated with a response-over-time diagram. The results of this 
chapter will be part of a manuscript in preparation. 
 
5.2 Experimental 
5.2.1 Chemicals 
Solvents for sample preparation and LC-MS analysis were HPLC grade and 
purchased from Fisher-Scientific (Schwerte, Germany) and Merck (Darmstadt, 
Germany). Heptafluorobutyric acid (HFBA) was from Fluka (Taufenkirchen, 
Germany), while tris-(2-carboxyethyl) phosphine hydrochloride (TCEP) and pyridoxal 
phosphate were from Sigma Aldrich (Taufenkirchen, Germany). [1’,2’,3’,4’,5’-13C5]-
adenosine was from Omicron Biochemicals (South Bend, IN, USA), [1’,2’,3’,4’,5’-
13C5]-MTA was prepared in house according to Robins et al. [69] (see chapter 3.2.2). 
KH2PO4 and K2HPo4 were from Merck (Darmstadt, Germany). The water used was 
purified by means of a PURELAB Plus system (ELGA LabWater, Celle, Germany). 
 
5.2.2 Internal standard preparation and stock solutions 
To obtain a 50 mM potassium phosphate buffer (pH=7.4) 4.01 mL of an 1 M K2HPO4 
solution were mixed with 0.99 mL of an 1 M KH2PO4 solution and filled up to 100 mL. 
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The pH value was checked and adjusted with phosphoric acid or potassium 
hydroxide, if necessary. 
A stock solution of stable-isotope labeled adenosine was prepared in aqueous 50 
mM potassium phosphate buffer (pH=7.4) and diluted to obtain a working solution of 
200 nM 13C5-adenosine in 50 mM potassium phosphate buffer. A solution of stable-
isotope labeled MTA (1 mM) in 0.1 M acetic acid was diluted in 50 mM potassium 
phosphate buffer (pH=7.4) to obtain a working solution of 1 µM 13C5-MTA. Pyridoxal 
phosphate and TCEP solutions were prepared in 50 mM potassium phosphate buffer 
(pH=7.4) with a concentration of 1mM and 10 mM, respectively. 
 
5.2.3 Hepatic tissue samples of mice with non alcoholic steatohepatitis 
Liver tissue samples from NASH and control mice described in 4.2.6 were also 
analyzed for MTAP activity. 
 
5.2.4 Preparation of liver samples 
Liver samples (10 – 30 mg) were weighted and homogenized in 500 µL of a 50 mM 
potassium phosphate buffer using “Precelly-Keramik-Kit 1.4 mm vials” (Peqlab 
Biotechnologie GmbH, Erlangen, Germany). The samples were homogenized twice 
at 5,500 rpm for 15 s with an intermediate 30-s pause using a Precellys® 24 
homogenizer (Peqlab Biotechnologie GmbH). Homogenates were stored on ice until 
measurement of MTAP activity, for which an aliquot corresponding to 1 mg liver was 
taken, diluted with buffer to a total volume of 200 µL and spiked with 25 µL each of 
pyridoxal phosphate and TCEP. The kinetic analysis was started by the addition of 25 
µL of 1 µM 13C5-MTA solution and 25 µL aliquots were taken at 0, 30, 60, 90, 120, 
150, 180, 240, 300 and 600 seconds. To quench the reaction, the aliquots were 
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transferred into 1.5-mL Eppendorf-cups containing 500 µL MeOH and 10 µL 13C5-
adenosine as internal standard. The sample was centrifuged at 9,000xg for 5 min at 
4°C and the supernatant was transferred to a 1.5-mL glass vial. The solvent was 
evaporated and the residues were reconstituted in 100 µL of aqueous 0.1 M acetic 
acid. 
 
5.2.5 Immunoblot of methylthioadenosine phosphorylase and mRNA 
determination 
The determination of total protein and MTAP for liver samples from NASH and control 
mice was performed as described previously [5]. Briefly, quantitative analysis of 
MTAP was performed by immunobloting. For protein isolation, samples were lysed in 
cell lysis-buffer (Cell Signaling, Danvers, MA, USA). Protein concentrations were 
determined using BCA protein assay reagent (Pierce, Rockford, IL, USA). Equal 
amounts of protein were denatured at 94°C for 10 min after addition of Roti-load-
buffer (Roth, Karlsruhe, Germany) and subsequently separated on NuPage-SDS-gels 
(Invitrogen, Groningen, The Netherlands). After transferring the proteins onto 
nitrocellulose-membranes (Invitrogen), the membranes were blocked in 5% 
milk/TBST for 1 h and incubated with a 1:1,000 dilution of primary monoclonal mouse 
anti-MTAP antibody (Abcam, Cambridge, UK) overnight at 4°C. A 1:3,000 dilution of 
mouse anti-Ig-AP (Santa Cruz) was used as secondary antibody. Detection was 
performed by Amersham ECL detection system (GE healthcare, München, Germany) 
using Amersham Hyperfilm TM ECL (GE Healthcare). 
Isolation of total cellular RNA and reverse transcription were performed as described 
previously [99]. Quantitative real time-PCR was performed with specific sets of 
primers by means of LightCycler technology (Roche, Mannheim, Germany) [99].  
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The experimental work described in chapter 5.2.6 was performed by Barbara Czech 
in the working group of PD Dr. Claus Hellerbrand, Department of Internal Medicine I. 
 
5.2.6 Instrumentation for methylthioadenosine phosphorylase activity 
determination 
The chromatographic conditions and the instrumentation were the same as used in 
chapter 4. Briefly, LC-ESI-MS/MS was performed using an Agilent 1200 SL HPLC 
system (Böblingen, Germany) and a PE Sciex API 4000 QTrap mass spectrometer 
(Applied Biosystems, Darmstadt, Germany). LC separation was carried out using an 
Atlantis T3 3µm (2.1 i.d. x 150 mm) reversed phase column (Waters, Eschborn, 
Germany) and a water-acetonitrile gradient with 0.1% acetic acid and 0.025% HFBA 
in both solvents. 
The API 4000 QTrap mass spectrometer was operated in positive mode with a 
source temperature of 500°C. Quantitative determination was performed with 
multiple-reaction monitoring (MRM) using the parameters listed in Table 3 (chapter 
4.2.9). Data acquisition and analysis were performed by Analyst version 1.5.1. 
 
5.2.7 Data analysis 
Determination of relative rate constants (workflow shown in Figure 27) was carried 
out using the analyte area response (area 13C5-MTA / area 13C5-adenosine) over 
time. A ln transformation results in a linear curve, whose slope is the value of the rate 
constant of the reaction.  
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Figure 27: Schematic workflow of the MTAP activity assay. 
After normalization, in a first approach to tissue weight, the rate constants of tumor 
and non-tumor tissue were compared with MTAP protein and MTA concentration. 
MTA concentrations were determined as described previously [55] (see also chapter 
4). 
5.3 Results and Discussion 
Figure 28 (left) shows that MTA accumulates by a factor of 2.25 in mice with NASH 
compared to control mice (p = 0.014). The activity assay of these samples results in 
a 50 % decrease in MTAP activity (p = 5.4E-5) in NASH mice compared with healthy 
mice (Figure 28, middle). 
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Figure 28: MTA concentration (p=0.014), MTAP activity (p=5.4E-5) and MTAP mRNA levels 
(p=0.69) in mice (n=5) with and without NASH. Values are normalized to healthy liver. 
 
Figure 29: Western blot of MTAP and actin (subset of all samples). 
As shown in Figure 28 (right) no significant differences in MTAP mRNA levels were 
observed (p = 0.69). The same holds true for MTAP protein levels (Figure 29, only a 
subset of all samples is shown). Therefore, one reason for an accumulation of MTA 
in NASH mice is a reduced activity of MTAP.  
A problem of this data set is that the MTA concentration and MTAP activity is 
normalized to tissue weight, while MTAP protein is corrected with actin, a marker for 
cell count. The Paigen/NASH mice show the same MTAP amount in total protein, but 
the liver of the Paigen/NASH mice contains fat. So the MTAP amount corrected with 
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total weight should be lower in liver of the Paigen/NASH mice compared to liver of 
healthy mice. And this normalization will result in no change of MTAP activity (data 
not shown) but will also increase the MTA concentration in the liver of the 
Paigen/NASH mice.  
This problem clearly indicates that a good parameter for normalization has to be 
selected and that it is necessary to have a method to determine MTAP quantitatively. 
 
5.4 Conclusions 
A stable isotope mass spectrometry based assay for the determination of MTAP 
activity in different samples was implemented and used in different types of liver 
biopsies. A decrease in MTAP activity was observed in the liver of NASH mice 
compared to healthy mice after normalization to tissue weight, which is the easiest 
normalization parameter. 
The quantification of MTAP protein was carried out in a first approach by Western 
Blot, but this method has the limitation, that it is only semi quantitative because the 
blots were detected on films. 
Nevertheless, the first preliminary results demonstrate the general applicability of the 
assay to determine MTAP activity in liver samples without using radio-isotopes. 
However, further steps are needed to optimize the method. This includes the use of 
protease inhibitors, which were in accordance with the literature not used in the 
preliminary experiments. Furthermore, buffer selection will be optimized to allow the 
determination of MTAP protein abundance in the same sample. The optimized assay 
will be useful to determine MTAP activity in different types of samples. 
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6. Summary and Outlook 
The methionine and polyamine metabolism is an interesting target in the study of 
tumor metabolism, e.g. polyamine synthesis is a measure of cell proliferation. Since 
many tumors lack MTAP, they are not capable of metabolizing MTA and metabolic 
changes in these pathways are expected caused by the assumed accumulation of 
MTA. An important prerequisite to study these changes is a sensitive and selective 
method to quantify MTA in samples like cell culture medium, cell pellets and different 
types of tumor biopsies. In the first part of this thesis a method for the quantification 
of MTA was developed and validated. The method was successfully used to prove 
the hypothesized accumulation of MTA in tumors in vitro and in vivo.  
In the next step, this method was expanded to key metabolites of the methionine and 
polyamine pathways and alterations in these pathways caused by a lack of MTAP 
were analyzed. Different types of tumors, including malignant melanoma, glioma, 
hepatocellular and renal carcinoma, and liver tissue samples from different types of 
liver diseases, including NASH and cirrhosis, showed in all cases an increase of 
MTA, SAM and putrescine in vitro as well as in vivo.  
To clarify further consequence of a loss of MTAP a mass spectrometry based activity 
assay was developed and MTAP activity in diseased and healthy tissue samples was 
measured. In case of NASH mice an inverse correlation between MTA concentration 
and MTAP activity was found after normalization to tissue weight, while MTAP protein 
and mRNA remained nearly constant. In further experiments this assay was 
successfully applied to human liver biopsies (a decrease of 13C5-MTA was observed 
over time), but for these samples the assay has to be further optimized.  
At the moment MTAP quantification is carried out by immunobloting and detection 
with photographic films. This procedure was improved by the usage of a CCD 
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camera, which results in densitometric analysis with the possibility to get quantitative 
values. As a standard recombinant MTAP (rMTAP) was used, but the MTAP antibody 
showed different binding kinetics to the native and recombinant MTAP. To solve this 
problem a quantification of MTAP via so called AQUA-peptides is planed. In 2003 the 
group of Steve Gygi presented a new technique for the quantification of proteins 
[100]. Using the common principle of a stable isotope labeled analog as an internal 
standard, the group synthesizes an AQUA-peptide. This is a synthetic tryptic peptide 
corresponding to a protein of interest and contains one stable isotope labeled amino 
acid resulting in a slight increase in molecular weight. The synthetic and native 
peptide will show the same properties during chromatography and ionization. 
However, by mass spectrometry both peptides are distinguished. For quantification a 
known amount of the AQUA-peptide is added to the protein sample and after tryptic 
digestion the sample is analyzed by HPLC-MS/MS. Using the AQUA-peptide as 
internal standard quantification is performed by the peak ratio. For quantification of 
MTAP it was decided to use two different AQUA-peptides and three MRM-transitions 
each. It is planed to set up an MRM-method for MTAP quantification at the 4000 
QTrap mass spectrometer.  
Normalization to tissue weight was not possible for human liver biopsies because the 
control samples were cirrhotic have more extra cellular matrix. Normalization to β-
actin or total protein content was tested, but the results were not satisfying. A 
possible explanation is that the liver biopsies do not contain any protease inhibitor 
because they were sampled for histological examination and the samples are now 
still stored over years. However, inhomogeneities in the samples are still remaining 
and not correctable with only one sample. To correct for inhomogeneities multiple 
sampling of biopsies is necessary. 
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Nevertheless, an activity assay using stable isotope labeled compounds is still not 
known in literature and will make the handling of the enzymatic activity a bit easier 
and safer. 
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8. Appendix  
Table A 1: Metabolite concentrations in liver samples of mice with non-alcoholic 
steatohepatitis (NASH). 
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BPE01_001 8,35 33,57 0,82 0,68 7481,69 9,90 0,00 99,18 27,14 699,57 6,39 1,41 522,95 2,84
BPE02_008 11,05 34,82 0,92 0,79 6084,33 11,57 0,01 109,89 23,43 654,33 5,46 1,58 588,17 2,95
BPE03_015 11,15 30,38 0,88 0,68 7634,80 10,35 0,02 97,14 19,85 615,38 3,88 1,02 463,62 2,68
BPE04_022 8,53 35,65 0,68 0,68 4521,61 11,11 0,01 87,50 22,25 625,38 3,67 1,03 464,12 2,83
BPE05_029 10,87 36,64 0,67 0,66 5393,15 9,91 0,01 115,81 26,33 732,37 6,08 1,22 591,41 3,15
Mean: 9,99 34,21 0,79 0,70 6223,12 10,57 0,01 101,91 23,80 665,41 5,10 1,26 526,05 2,89
Stdev.: 1,42 2,42 0,12 0,05 1339,78 0,74 0,01 11,12 2,99 49,70 1,25 0,24 62,99 0,17
rel. Stdev.: 0,14 0,07 0,15 0,08 0,22 0,07 0,63 0,11 0,13 0,07 0,25 0,19 0,12 0,06
BPE06_002 0,72 19,85 0,57 0,73 4271,24 27,66 0,04 14,05 26,42 326,83 5,10 1,05 137,48 0,60
BPE07_009 3,16 26,66 1,56 2,43 6939,10 38,27 0,03 22,09 66,30 568,05 7,32 1,45 293,18 1,18
BPE08_016 0,96 13,98 0,56 1,64 4901,53 28,52 0,08 10,52 34,25 358,27 6,35 1,12 134,69 0,68
BPE09_023 1,90 11,27 1,54 1,30 4378,67 34,33 0,11 7,02 28,80 245,85 4,79 0,76 52,46 0,23
BPE10_030 2,07 11,02 1,38 1,80 5273,19 29,86 0,09 6,61 34,22 403,18 5,46 1,10 115,02 0,44
Mean: 1,76 16,56 1,12 1,58 5152,75 31,73 0,07 12,06 38,00 380,43 5,81 1,09 146,57 0,63
Stdev.: 0,97 6,67 0,51 0,63 1077,60 4,47 0,03 6,37 16,18 119,58 1,03 0,25 88,84 0,35
rel. Stdev.: 0,55 0,40 0,46 0,40 0,21 0,14 0,50 0,53 0,43 0,31 0,18 0,22 0,61 0,56
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Table A 2: Metabolite concentrations in liver samples of mice with liver cirrhosis. 
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1 3,86 13,70 0,38 0,22 1512,33 5,01 16,03 6,22 2271,23 635,62
2 4,98 7,66 0,63 0,22 1736,24 3,81 21,19 6,56 2454,13 623,85
3 4,33 31,19 0,74 0,81 1532,18 5,89 27,72 24,03 2329,21 675,74
Mean 4,39 17,52 0,58 0,42 1593,58 4,90 21,65 12,27 2351,52 645,07
Stdev.: 0,56 12,22 0,18 0,34 123,94 1,05 5,86 10,19 93,47 27,21
rel. Stdev.: 0,13 0,70 0,31 0,82 0,08 0,21 0,27 0,83 0,04 0,04
13 1,05 8,94 0,43 3,68 927,17 94,09 13,92 77,95 2047,24 405,51
14 2,07 6,35 0,31 3,46 894,44 110,19 17,76 86,48 2388,89 405,56
15 0,92 7,23 0,48 2,73 672,35 63,26 28,03 69,32 2348,48 363,64
Mean 1,35 7,51 0,41 3,29 831,32 89,18 19,90 77,92 2261,54 391,57
Stdev.: 0,63 1,31 0,09 0,50 138,64 23,85 7,30 8,58 186,68 24,19
rel. Stdev.: 0,47 0,18 0,22 0,15 0,17 0,27 0,37 0,11 0,08 0,06
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Table A 3: Metabolite concentrations in mice glioma samples.  
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HC1_001 19,38 492,27 0,07 0,85 9,85 7,16 < 0 13,20 24,43 329,90 1,01 0,20 144,33 0,34
HC2_005 13,41 468,99 0,01 0,63 5,93 5,43 < 0 12,25 20,08 204,26 1,30 0,17 138,76 0,46
HC3_009 13,14 439,22 < 0 0,47 4,35 4,59 < 0 7,33 19,49 185,88 1,24 0,19 132,55 0,44
HC4_013 16,00 478,26 < 0 0,81 5,51 5,57 < 0 8,17 23,04 219,13 1,57 0,25 155,65 0,66
Mean: 15,48 469,68 0,04 0,69 6,41 5,69 < 0 10,24 21,76 234,79 1,28 0,20 142,82 0,47
Stdev.: 2,90 22,45 0,05 0,17 2,39 1,08 n.d. 2,91 2,36 64,84 0,23 0,03 9,81 0,13
rel. Stdev.: 18,74 4,78 121,12 25,07 37,23 18,93 n.d. 28,47 10,87 27,62 18,13 16,37 6,87 28,23
NT1_002 11,38 545,87 0,08 0,95 7,66 60,09 0,04 8,90 33,12 423,39 5,37 0,37 168,35 0,36
NT2_006 9,85 515,00 0,07 0,69 6,90 24,10 < 0 6,65 27,40 220,50 3,24 0,25 185,50 0,69
NT3_010 10,42 455,76 0,16 0,63 7,58 35,45 < 0 5,84 24,61 353,94 4,94 0,27 179,39 0,67
NT4_014 16,04 503,57 0,03 0,55 4,50 35,25 < 0 6,29 23,18 385,71 9,21 0,50 153,21 0,50
Mean: 11,92 505,05 0,09 0,70 6,66 38,72 0,04 6,92 27,08 345,89 5,69 0,35 171,61 0,56
Stdev.: 2,81 37,40 0,05 0,17 1,48 15,20 n.d. 1,36 4,39 88,28 2,52 0,12 14,17 0,15
rel. Stdev.: 23,60 7,41 59,75 24,77 22,21 39,25 n.d. 19,69 16,23 25,52 44,37 33,25 8,26 27,61
T1_003 1,19 24,79 1,07 2,07 195,86 127,81 0,57 10,12 68,64 656,80 17,46 1,75 297,63 2,21
T2_007 1,84 36,62 1,02 1,95 172,62 120,91 0,64 9,96 66,92 646,39 19,85 1,98 322,05 3,11
T3_011 1,03 53,18 1,00 2,25 172,24 120,07 0,14 9,40 68,23 608,70 39,13 1,83 289,63 9,13
T4_015 1,86 53,08 0,93 1,92 127,47 140,66 0,74 11,65 62,64 675,82 18,24 1,48 301,10 3,79
Mean: 1,48 41,92 1,00 2,05 167,05 127,36 0,52 10,28 66,61 646,93 23,67 1,76 302,60 4,56
Stdev.: 0,43 13,82 0,06 0,15 28,60 9,52 0,27 0,96 2,75 28,25 10,36 0,21 13,83 3,11
rel. Stdev.: 29,21 32,96 5,83 7,47 17,12 7,47 51,18 9,36 4,12 4,37 43,75 11,83 4,57 68,27
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Table A 4: Metabolite concentrations in human renal carcinoma samples. 
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Tumor 1 0,62 1,68 1,28 6,99 0,71 12,53 < LOD 2,19 6,26 4,15 5,73 0,38 3,11 1,26
Tumor 2 0,91 0,43 2,35 3,12 0,69 4,75 < LOD 1,41 3,85 2,13 2,85 1,08 1,26 0,50
Tumor 3 1,42 1,50 1,05 2,74 0,97 1,80 < LOD 1,95 3,31 3,61 6,51 0,38 1,42 2,11
Tumor 4 0,28 2,32 4,10 2,54 0,68 7,28 < LOD 2,24 2,05 1,27 7,40 0,40 0,96 1,54
Tumor 5 0,47 1,92 3,77 0,66 0,63 3,46 < LOD 1,41 0,81 1,41 0,87 0,25 0,74 0,53
Mean: 0,74 1,57 2,51 3,21 0,74 5,97 n.d. 1,84 3,25 2,51 4,67 0,50 1,50 1,19
Stdev.: 0,44 0,71 1,39 2,31 0,13 4,18 n.d. 0,40 2,05 1,31 2,73 0,33 0,94 0,69
rel. Stdev: 0,60 0,45 0,56 0,72 0,18 0,70 n.d. 0,22 0,63 0,52 0,58 0,67 0,63 0,58
Healthy 1 0,51 0,69 1,34 1,11 1,42 1,62 < LOD 1,37 1,05 1,32 1,08 1,11 1,27 1,60
Healthy 2 1,40 0,78 0,86 0,96 0,58 1,25 < LOD 0,62 0,98 0,94 0,89 0,85 0,89 0,63
Healthy 3 1,16 1,50 1,10 0,77 0,66 0,55 < LOD 0,44 0,91 0,68 0,52 0,55 0,73 0,47
Healthy 4 1,18 0,90 1,20 0,92 1,20 0,26 < LOD 1,33 0,88 0,88 0,98 1,36 1,07 0,37
Healthy 5 0,76 1,12 0,50 1,24 1,14 1,32 < LOD 1,25 1,18 1,18 1,53 1,13 1,05 1,94
Mean: 1,00 1,00 1,00 1,00 1,00 1,00 n.d. 1,00 1,00 1,00 1,00 1,00 1,00 1,00
Stdev.: 0,36 0,32 0,33 0,18 0,36 0,57 n.d. 0,44 0,12 0,25 0,36 0,31 0,20 0,72
rel. Stdev: 0,36 0,32 0,33 0,18 0,36 0,57 n.d. 0,44 0,12 0,25 0,36 0,31 0,20 0,72
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11. Summary 
5’-Deoxy-5’-methylthioadenosine (MTA) is formed in the course of the synthesis of 
polyamines from S-adenosylmethionine (SAM). Tumors lack the enzyme 
methylthioadenosine phosphorylase (MTAP), which metabolizes MTA, and should 
accumulate MTA. In a first step, a method for quantification of MTA by liquid 
chromatography-mass spectrometry was developed and the postulated accumulation 
of MTA in tumors and tumor cell lines lacking MTAP could be demonstrated. To 
elucidate further consequences of a lack of MTAP in tumor cells, the method was 
expanded to most of the metabolites in the methionine and polyamine pathways. 
With this method it could be shown, that MTA, putrescine and SAM correlate in 
concentration. So, the accumulation of MTA has a direct influence on the synthesis of 
the polyamines. This correlation could be observed in different tumor species, e.g. 
malignant melanoma, HCC, renal carcinoma and brain tumors, as well as in different 
liver diseases (fibrosis, cirrhosis and hepatocellular carcinoma). To clarify a relation 
between MTA concentration and MTAP abundance a mass spectrometry based 
activity-assay for MTAP has been set up, using stable isotope labeled MTA as 
substrate. The decrease in stable isotope labeled MTA was measured over time by 
liquid chromatography-mass spectrometry and rate constants were determined. For 
mice with fatty liver disease an inverse correlation of MTA concentration and MTAP 
activity (both normalized to tissue weight) was observed. The assay works also in 
human tumor biopsies, but the analysis of the results is much more difficult because 
the control tissue is cirrhotic. Normalization to tissue weight is not possible due to the 
different nature of both tissue specimens. 
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In a next step MTAP protein should be quantified by AQUA peptides and liquid 
chromatography mass spectrometry for a better understanding of the still measured 
activity. 
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12. Zusammenfassung 
5’-Deoxy-5’-methylthioadenosin (MTA) entsteht im Zuge der Polyaminsynthese aus 
S-Adenosylmethionin (SAM). Das für den Abbau von MTA nötige Enzym 
Methylthioadenosinphosphorylase (MTAP) ist in vielen Tumoren nicht vorhanden 
oder zumindest in seiner Aktivität stark vermindert und somit wird postuliert, dass in 
Tumoren MTA akkumuliert. Zuerst wurde eine Methode zur quantitativen 
Bestimmung von MTA mit Flüssigkeitschromatographie-Tandem-
Massenspektrometrie entwickelt, mit der dann die vermutete Akkumulation von MTA 
in Tumoren und Tumor-Zell-Linien mit reduziertem MTAP-Level nachgewiesen 
werden konnte. Um weitere Folgen eines reduzierten MTAP-Levels in Tumoren zu 
klären, wurde die Methode auf die meisten Metabolite des Methionin- und 
Polyaminstoffwechselweges erweitert und es konnte gezeigt werden, dass eine 
positive Korrelation zwischen MTA, SAM und Putrescin besteht, die sowohl in 
verschiedenen Tumoren (z. B. Melanom, Gliom, Nierenkarzinom und Lebertumor) als 
auch unterschiedlichen Lebererkrankungen (Fettleber, Zirrhose und Lebertumor) 
beobachtet werden konnte. Zur Klärung des Zusammenhangs zwischen MTA-
Konzentration und Menge an MTAP wurde ein Aktivitäts-Assay für MTAP entwickelt, 
bei dem stabil isotopen markiertes MTA verwendet wurde. Die zeitliche Abnahme 
des Substrates wurde mit Flüssigkeitschromatographie-Tandem-
Massenspektrometrie verfolgt und Geschwindigkeitskonstanten ermittelt. Bei Mäusen 
mit Fettleber konnte eine inverse Korrelation von MTA-Konzentration und MTAP-
Aktivität (normalisiert auf Lebergewicht) beobachtet werden. Somit akkumuliert MTA 
in den Lebern der kranken Mäuse auf Grund eines langsameren MTA-Abbaus. In 
humanem Lebergewebe, welches mit diesem Assay ebenfalls analysiert wurde, sind 
die Ergebnisse schwerer zu interpretieren, da das Kontrollgewebe in diesem Fall 
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bereits zirrhotisch ist. Eine Normalisierung auf Gewicht ist auf Grund des großen 
Unterschiedes zwischen gesundem und zirrhotischem Lebergewebe nicht sinnvoll. 
In einem nächsten Schritt soll die MTAP-Proteinmenge mit AQUA-Peptiden und 
Flüssigkeitschromatographie-Tandem-Massenspektrometrie bestimmt werden, um 
die gewonnenen Aktivitätswerte besser verstehen zu können. 
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